Cocaine
View on Wikipedia
| Clinical data | |
|---|---|
| Pronunciation | kə(ʊ)ˈkeɪn |
| Trade names | Neurocaine,[1] Goprelto,[2] Numbrino,[3] others |
| Other names | Benzoylmethylecgonine |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Dependence liability | Physical: Low Psychological: High[4] |
| Addiction liability | High[5] |
| Routes of administration | Topical, by mouth, insufflation, intravenous, inhalation |
| Drug class | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability |
|
| Metabolism | Liver, CYP3A4 |
| Metabolites | Norcocaine, benzoylecgonine, cocaethylene (when consumed with alcohol) |
| Onset of action | Seconds to minutes[13] |
| Duration of action | 20 to 90 minutes[13] |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.030 |
| Chemical and physical data | |
| Formula | C17H21NO4 |
| Molar mass | 303.358 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 98 °C (208 °F) |
| Boiling point | 187 °C (369 °F) |
| Solubility in water | 1.8g/L (22 °C) |
| |
| |
| Data page | |
| Cocaine (data page) | |
| | |
Cocaine is a central nervous system stimulant and tropane alkaloid derived primarily from the leaves of two coca species native to South America: Erythroxylum coca and E. novogranatense.[14][15][16][17][18] Coca leaves are processed into cocaine paste, a crude mix of coca alkaloids from which cocaine base is isolated and converted to cocaine hydrochloride, commonly known as "cocaine".[18] Cocaine was once a standard topical medication as a local anesthetic with intrinsic vasoconstrictor activity, but its high abuse potential, adverse effects, and cost have limited its use and led to its replacement by other medicines.[19][20][21] "Cocaine and its combinations" are formally excluded from the WHO Model List of Essential Medicines.[22]
Street cocaine is commonly snorted, injected, or smoked as crack cocaine, with effects lasting up to 90 minutes depending on the route.[13][23] Cocaine acts pharmacologically as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI),[7][24][17] producing reinforcing effects such as euphoria, increased alertness, concentration, libido, and reduced fatigue and appetite.[25]
Cocaine has numerous adverse effects. Acute use can cause vasoconstriction, tachycardia, hypertension, hyperthermia, seizures, while overdose may lead to stroke, heart attack, or sudden cardiac death.[17][13][26] Cocaine also produces a spectrum of psychiatric symptoms including agitation, paranoia, anxiety, irritability, stimulant psychosis, hallucinations, delusions, violence, as well as suicidal and homicidal thinking.[27][17] Prenatal exposure poses risks to fetal development.[28][29][30][31] Chronic use may result in cocaine dependence, withdrawal symptoms, neurotoxicity, and nasal damage, including cocaine-induced midline destructive lesions.[32][33][34][35][36][37] No approved medication exists for cocaine dependence, so psychosocial treatment is primary.[38][39] Cocaine is frequently laced with levamisole to increase bulk.[40][41] This is linked to vasculitis (CLIV) and autoimmune conditions (CLAAS).[42][43]
Coca cultivation and its subsequent processes occur primarily Latin America, especially in the Andes of Bolivia, Peru, and Colombia, though cultivation is expanding into Central America, including Honduras, Guatemala, and Belize.[18][44][45][46][47] Violence linked to the cocaine trade continues to affect Latin America and the Caribbean and is expanding into Western Europe, Asia, and Africa as transnational organized crime groups compete globally.[48][49] Cocaine remains the world's fastest-growing illicit drug market.[50][51] Coca chewing dates back at least 8,000 years in South America.[52] Large-scale cultivation occurred in Taiwan and Java prior to World War II.[53][54] Decades later, the cocaine boom marked a sharp rise in illegal cocaine production and trade, beginning in the late 1970s and peaking in the 1980s.[55] Cocaine is regulated under international drug control conventions, though national laws vary: several countries have decriminalized small quantities.[56][57][58][59]
Uses
[edit]Coca leaves have been used by Andean civilizations since ancient times.[60] In ancient Wari culture,[61] Inca culture, and through modern successor indigenous cultures of the Andes Mountains, coca leaves are chewed, taken orally in the form of a tea, or alternatively, prepared in a sachet wrapped around alkaline burnt ashes, and held in the mouth against the inner cheek; it has traditionally been used as an anorectic and to combat the effects of cold and altitude sickness,[62][63] although its actual effectiveness has never been systematically studied.[64]
Globally, in 2019, cocaine was used by an estimated 20 million people (0.4% of adults aged 15 to 64 years). The highest prevalence of cocaine use was in Australia and New Zealand (2.1%), followed by North America (2.1%), Western and Central Europe (1.4%), and South and Central America (1.0%).[65] Since 1961, the Single Convention on Narcotic Drugs has required countries to make recreational use of cocaine a crime.[66] In the United States, cocaine is regulated as a Schedule II drug under the Controlled Substances Act, meaning that it has a high potential for abuse but has an accepted medical use.[67] While rarely used medically today, its accepted uses include serving as a topical local anesthetic for the upper respiratory tract and as an antihemorrhagic agent to stop bleeding in the mouth, throat, and nasal cavities.[68]
Traditional medicine
[edit]Coca leaves
[edit]
It is legal for people to use coca leaves in the Andean Community, such as Peru and Bolivia, where they are chewed, consumed in the form of tea, or are sometimes incorporated into food products.[69] Coca leaves are typically mixed with an alkaline substance (such as slaked lime) and chewed into a wad that is retained in the buccal pouch (mouth between gum and cheek, much the same as chewing tobacco is chewed) and sucked of its juices. The juices are absorbed slowly by the mucous membrane of the inner cheek and by the gastrointestinal tract when swallowed.
Coca tea
[edit]
Coca herbal infusion (also referred to as coca tea) is used in coca-leaf producing countries much as any herbal medicinal infusion would elsewhere in the world. The free and legal commercialization of dried coca leaves under the form of filtration bags to be used as "coca tea" has been actively promoted by the governments of Peru and Bolivia for many years as a drink having medicinal powers. In Peru, the National Coca Company, a state-run corporation, sells cocaine-infused teas and other medicinal products and also exports leaves to the U.S. for medicinal use.[70] The effects of drinking coca tea are mild stimulation and mood lift.[71]
In 1986 an article in the Journal of the American Medical Association revealed that U.S. health food stores were selling dried coca leaves to be prepared as an infusion as "Health Inca Tea". While the packaging claimed it had been "decocainized", no such process had actually taken place. The article stated that drinking two cups of the tea per day gave a mild stimulation, increased heart rate, and mood elevation, and the tea was essentially harmless.[72]
Ypadu
[edit]
Ypadú or ypadu (also known as mambé) is an unrefined, unconcentrated powder made from toasted coca leaves and the ash of various other plants. It is traditionally prepared and consumed by indigenous tribes in the Northwest Amazon.[73] Like coca teas consumed in Peru to adapt to sickness induced by high elevation, it has a long ethnobotanical history and cultural associations.
Medical
[edit]Karl Koller's groundbreaking discovery of cocaine as a local anesthetic is regarded as the second most significant advance in the history of anesthesia. Although cocaine was once widely preferred for topical anesthesia, the search for replacement agents intensified due to rising costs, strict regulations, and its habit-forming potential.[21] Cocaine is not included on the WHO Model List of Essential Medicines; the list formally excludes "cocaine and its combinations" as therapeutic alternatives to ophthalmological preparations.[22]
Today, the US Drug Enforcement Administration (DEA) classifies cocaine as a Schedule II drug, recognizing its high potential for abuse but still permitting its limited use for medical purposes. However, current pharmacoepidemiological trends suggest that cocaine may soon reach the point where, in practical terms, it is no longer used medically in health care as a Schedule II substance. This report may prompt some states (such as North Dakota) and institutions to reconsider whether further efforts to identify alternative agents are needed. As physician boards—but not pharmacy boards—continue to assess knowledge of licit cocaine, attention may shift toward drugs with more contemporary medical use.[21]
Cocaine is rarely prescribed in modern medicine due to its high potential for abuse and significant risk of adverse effects; its use is now almost exclusively limited to health facilities for specific diagnostic procedures or surgeries.
Topical
[edit]Cocaine is used in medical practice as a topical medication.[21] Because it is not absorbed into the bloodstream in significant amounts when used this way, topical application does not produce the psychoactive effects associated with recreational cocaine use.
Topical anesthetic
[edit]
Cocaine is sometimes used in otorhinolaryngology as a topical anesthetic and vasoconstrictor to help control pain and bleeding during surgery of the nose, mouth, throat, or lacrimal duct. It is also used for topical airway anaesthesia for procedures such as awake fibreoptic bronchoscopy or intubation. Although some absorption and systemic effects may occur, the use of cocaine as a topical anesthetic and vasoconstrictor is generally safe, rarely causing cardiovascular toxicity, glaucoma, and pupil dilation.[74][19] Occasionally, cocaine is mixed with adrenaline and sodium bicarbonate and used topically for surgery, a formulation called Moffett's solution.[75] It is occasionally used in surgeries involving the pharynx or nasopharynx to reduce pain, bleeding, and vocal cord spasm.[76]
Nasal solution cocaine hydrochloride (Goprelto), an ester used for intranasal application, was approved for medical use in the United States in December 2017, and is indicated for the introduction of topical anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.[77][2] Cocaine hydrochloride (Numbrino) was approved for medical use in the United States in January 2020.[78][3] Headache and epistaxis are the most frequently reported adverse reactions with Goprelto,[2] while hypertension and tachycardia-including sinus tachycardia-are most common with Numbrino.[3]
Ophthalmological use
[edit]Cocaine eye drops have traditionally been used by neurologists when examining people suspected of having Horner syndrome. In Horner syndrome, sympathetic innervation to the eye is blocked. In a healthy eye, cocaine stimulates the sympathetic nervous system (SNS) by inhibiting norepinephrine reuptake, causing the pupil to dilate. In patients with Horner syndrome, sympathetic innervation to the eye is disrupted, so the affected pupil does not dilate in response to cocaine and remains constricted, or dilates to a lesser extent than the unaffected eye, which also receives the eye drop test. If both eyes dilate equally, the patient does not have Horner syndrome.[79]
However, apraclonidine has largely replaced cocaine as the first-line pharmacologic agent for the diagnosis of Horner syndrome in routine clinical practice.[80][81][20]
Recreational
[edit]
Recreational cocaine is typically not taken by mouth due to its poor bioavailability, instead it is usually snorted or injected. Cocaine hydrochloride can also be chemically converted into its free base form, crack cocaine, which can be vaporized.
Cocaine is a central nervous system stimulant.[82] Its effects can last from 15 minutes to an hour. The duration of cocaine's effects depends on the amount taken and the route of administration.[83] Cocaine can be in the form of fine white powder and has a bitter taste. Crack cocaine is a smokeable form of cocaine made into small "rocks" by processing cocaine with sodium bicarbonate (baking soda) and water.[13][26]
Cocaine use leads to increases in alertness, feelings of well-being and euphoria, increased energy and motor activity, and increased feelings of competence and sexuality.[84]
Expectations about cocaine's effects—both positive and negative—can influence how people feel after using it. Surprisingly, expecting negative effects may increase the drug's perceived positive impact, making quitting or avoiding cocaine more difficult for some individuals.[85]
Analysis of the correlation between the use of 18 various psychoactive substances shows that cocaine use correlates with other "party drugs" (such as MDMA or amphetamines), as well as with heroin and benzodiazepines use, and can be considered as a bridge between the use of different groups of drugs.[86]
Insufflation
[edit]
Nasal insufflation (known colloquially as "snorting", "sniffing", or "blowing") is a common method of ingestion of recreational powdered cocaine.[88] The drug coats and is absorbed through the mucous membranes lining the nasal passages. Cocaine's desired euphoric effects are delayed when snorted through the nose by about five minutes. This occurs because cocaine's absorption is slowed by its constricting effect on the blood vessels of the nose.[13] Insufflation of cocaine also leads to the longest duration of its effects (60–90 minutes).[13] When insufflating cocaine, absorption through the nasal membranes is approximately 30–60%[89]
In a study of cocaine users, the average time taken to reach peak subjective effects was 14.6 minutes.[90] Any damage to the inside of the nose is due to cocaine constricting blood vessels—and therefore restricting blood and oxygen/nutrient flow—to that area, which, after chronic use, may cause "cocaine nose."
Most banknotes have traces of cocaine on them; this has been confirmed by studies done in several countries.[91] In 1994, the U.S. 9th Circuit Court of Appeals cited findings that in Los Angeles, three out of four banknotes were tainted by cocaine or another illicit drug.[92][93]
Snuff spoons, hollowed-out pens, cut straws, pointed ends of keys,[94] long fingernails or artificial nails, and (clean) tampon applicators are also used to insufflate cocaine. The cocaine typically is poured onto a flat, hard surface (such as a mobile phone screen, plate, mirror, CD case or book) and divided into "bumps", "lines" or "rails", and then insufflated.[95] A 2001 study reported that the sharing of straws used to "snort" cocaine can spread blood diseases such as hepatitis C.[96]
Cocaine spoon
[edit]
Historically, snuff spoons were used for cocaine in the 20th century, hence the names "cocaine spoon" and "coke spoon". Some local statutes in the US treat spoons that are too small and thus "unsuited for the typical, lawful uses of a spoon" as drug paraphernalia.[97][98][99]
Injection
[edit]Subjective effects not commonly shared with other methods of administration include a ringing in the ears moments after injection (usually when over 120 milligrams) lasting 2 to 5 minutes including tinnitus and audio distortion. This is colloquially referred to as a "bell ringer". In a study of cocaine users, the average time taken to reach peak subjective effects was 3.1 minutes.[90] The euphoria passes quickly. Aside from the toxic effects of cocaine, there is also the danger of circulatory emboli from the insoluble substances that may be used to cut the drug. As with all injected illicit substances, there is a risk of the user contracting blood-borne infections if sterile injecting equipment is not available or used.
Inhalation
[edit]Cocaine paste
[edit]Coca paste (paco, basuco, oxi, pasta) is a crude extract of the coca leaf which contains 40% to 91% cocaine freebase along with companion coca alkaloids and varying quantities of benzoic acid, methanol, and kerosene. The caustic reactions associated with the local application of coca paste prevents its use by oral, intranasal, mucosal, intramuscular, intravenous or subcutaneous routes. Coca paste can only be smoked when combined with a combustible material such as tobacco or cannabis.[100]
Crude cocaine preparation intermediates are marketed as cheaper alternatives to pure cocaine to local markets while the more expensive end product is exported to United States and European markets. Freebase cocaine paste preparations can be smoked. The psychological and physiological effects of the paco are quite severe.[101][102] Media usually report that it is extremely toxic and addictive.[103][104][105] According to a study by Intercambios, media appear to exaggerate the effects of paco. These stereotypes create a sense that nothing can be done to help a paco addict and thus stand in the way of rehabilitation programs.[106]
Crack cocaine
[edit]
Powder cocaine (cocaine hydrochloride) must be heated to a high temperature to be smoked (about 197 °C), and considerable decomposition/burning occurs at these high temperatures. This effectively destroys some of the cocaine and yields a sharp, acrid, and foul-tasting smoke. Cocaine base/crack can be smoked because it vaporizes with little or no decomposition at 98 °C (208 °F),[107] which is below the boiling point of water.
Contraindications
[edit]Cocaine should not be used in individuals with a known allergy or hypersensitivity to the drug or any components of its topical formulation. It is also contraindicated in elderly patients and those with a history of hypertension or cardiovascular disease.[108]
Pregnancy
[edit]Prenatal cocaine exposure (PCE) may occur when a pregnant woman uses cocaine.[28][29][30][31]
Under the former FDA pregnancy category system, cocaine was classified as a Category C drug. Its potential to cause harm to the fetus is not fully known, so it should only be administered to pregnant women if clearly necessary.[108]
Cocaine can act as a teratogen, having various effects on the developing fetus.[109] Some common teratogenic defects caused by cocaine include hydronephrosis, cleft palate, polydactyly, and down syndrome.[109] Cocaine as a drug has a low molecular weight and high water and lipid solubility which enables it to cross the placenta and fetal blood-brain barrier.[110] Because cocaine is able to pass through the placenta and enter the fetus, the fetus' circulation can be negatively affected. With restriction of fetal circulation, the development of organs in the fetus can be impacted, even resulting in intestines developing outside of the fetus' body.[109] Cocaine use during pregnancy can also result in obstetric labor complications such as, placental abruption,[111] preterm birth or delivery, uterine rupture, miscarriage, and stillbirth.[109][112] Prenatal cocaine exposure may cause subtle cognitive deficits and lower the chance of above-average IQ by age 4, but supportive caregiving can significantly improve outcomes.[113]
Breastfeeding
[edit]Mothers utilizing recreational drugs, such as cocaine, methamphetamines, PCP, and heroin, should not breastfeed.[114][115]: 13
The March of Dimes said "it is likely that cocaine will reach the baby through breast milk," and advises the following regarding cocaine use during pregnancy:
Cocaine use during pregnancy can affect a pregnant woman and her unborn baby in many ways. During the early months of pregnancy, it may increase the risk of miscarriage. Later in pregnancy, it can trigger preterm labor (labor that occurs before 37 weeks of pregnancy) or cause the baby to grow poorly. As a result, cocaine-exposed babies are more likely than unexposed babies to be born with low birth weight (less than 5.5 lb or 2.5 kg). Low-birthweight babies are 20 times more likely to die in their first month of life than normal-weight babies, and face an increased risk of lifelong disabilities such as mental retardation and cerebral palsy. Cocaine-exposed babies also tend to have smaller heads, which generally reflect smaller brains. Some studies suggest that cocaine-exposed babies are at increased risk of birth defects, including urinary tract defects and, possibly, heart defects. Cocaine also may cause an unborn baby to have a stroke, irreversible brain injury, or a myocardial infarction.[116]
Adverse effects
[edit]-
A 2010 study ranking various illegal and legal drugs based on statements by drug-harm experts in the UK. Crack cocaine and cocaine were found to be the third and fifth overall most dangerous drugs respectively.[117]
-
2007 delphic analysis regarding 20 popular recreational drugs based on expert opinion in the UK. Cocaine was ranked the 2nd in dependence and physical harm and 3rd in social harm.[118]
Cardiac complications
[edit]Cocaine use can cause serious heart problems like sudden death, heart inflammation, arrhythmias, and heart attacks. It triggers coronary artery spasms, increases blood clot risk, and accelerates atherosclerosis, especially with long-term use. The severity of heart disease often relates to how long and how often cocaine is used.[119] It can also become a serious risk at high doses due to cocaine's blocking effect on cardiac sodium channels.[120]
Levamisole syndromes
[edit]Levamisole is one of the most common adulterants found in illicit cocaine, with studies showing that between 2009 and 2016, 50–70% of all cocaine specimens worldwide contained levamisole, reflecting similar high rates of contamination across North America and Europe.[41] Before trafficking to the United States, the cocaine is frequently adulterated with levamisole.[40] By October 2017, this figure had risen further, with the DEA reporting that 87% of seized and analyzed cocaine bricks in the United States contained levamisole, making it the most common adulterant in cocaine at that time.[121]
In the body, levamisole is converted into aminorex, a substance with amphetamine-like stimulant effects and a long duration of action.[122] Levamisole-adulterated cocaine is associated with cocaine- and levamisole-induced vasculitis (CLIV) and cocaine/levamisole-associated autoimmune syndrome (CLAAS).[42][43] Reagent testing kits can be used to detect the presence of cocaine and levamisole.[123]
Levamisole-induced necrosis syndrome
[edit]Levamisole-induced necrosis syndrome (LINES) is a complication characterized by necrosis resulting from exposure to levamisole, a medication with immunomodulatory properties. While LINES can occur with levamisole use alone, most reported cases are associated with the use of cocaine adulterated with levamisole as a cutting agent. This syndrome is marked by skin necrosis, often affecting areas such as the ears, face, and extremities, and is thought to result from levamisole's effects on blood vessels and the immune system.[124]
Cocaine/levamisole-associated syndromes
[edit]The skin necrosis associated with levamisole toxicity ranges from leukocytoclastic vasculitis to occlusive vasculopathy. Several cases of severe agranulocytosis associated with cocaine use have been reported since 2006. With the recently recognized dermal disease, the face and ears are commonly affected, especially the bilateral helices and cheeks. However, there have also been case reports of involvement of the abdomen, chest, lower buttocks and legs.[125][126]
During the mid-2010s, levamisole was found in most cocaine products available in both the United States and Europe.[127] Levamisole is known to cause an acute condition involving a severe and dangerous lowered white blood cell count, known as agranulocytosis, in cocaine users, and may also accentuate cocaine's effects.[128][129]
Clinical studies have shown that taking levamisole at doses of 50–200 mg per day can lead to agranulocytosis in approximately 0.08–5% of patients.[130]
Cocaine- and levamisole-induced vasculitis
[edit]Cocaine- and levamisole-induced vasculitis (CLIV) is often used as an umbrella term for the vasculitic and necrotic complications seen with levamisole-adulterated cocaine, including both LINES and CLAAS.[42]
Cocaine and levamisole-adulterated cocaine (LAC) can cause cocaine-induced vasculitis (CIV) that mimics primary anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), presenting as cocaine-induced midline destructive lesions, LAC vasculopathy, or CIV. These conditions involve immune activation through NETosis and ANCA formation, leading to tissue damage. Diagnosis is challenging due to symptom overlap and undisclosed drug use, making clinical suspicion and drug history essential for proper management.[131]
Cocaine/levamisole-associated autoimmune syndrome
[edit]The broader cocaine/levamisole-associated autoimmune syndrome (CLAAS) includes LINES as a subset and is also common, but LINES is more specifically and frequently cited in the context of street cocaine adulteration.[43]
Levamisole has become a common additive to illicit cocaine. It is thought to intensify the "high" by releasing dopamine in the brain, acts as a bulking agent, and is a difficult adulterant to recognize. Potential risks of levamisole-laced cocaine include autoimmune disease, neutropenia, arthralgias, retiform purpura, skin necrosis, and fever.[132]
Mortality
[edit]Persons with regular or problematic use of cocaine have a significantly higher mortality rate, and are specifically at higher risk of traumatic deaths and deaths attributable to infectious disease.[133] In 2025, the Liberty House Clinic in the United Kingdom noted that chronic cocaine usage in fact had a higher risk of death than alcoholism.[134]
Neurotoxicity
[edit]Cocaine is considered neurotoxic due to its damaging effects on the brain and nervous system.[135][136][34][137][138][139] Research has shown that both acute and chronic cocaine use can lead to significant reductions in cerebral blood flow, disrupt neurovascular interactions, and impair brain function. These changes are associated with nerve injury, cognitive deficits, and an increased risk of cerebrovascular accidents such as strokes. Brain imaging studies consistently report that individuals who misuse cocaine exhibit structural and functional abnormalities compared to non-users, supporting the classification of cocaine as a neurotoxic substance.[34]
Cocaine use damages gray matter in brain regions critical for memory, attention, and emotion, leading to cognitive and behavioral impairments. It also disrupts dopamine levels and blood flow, accelerating brain aging and causing long-term neurological harm.[140]
Psychiatric symptoms
[edit]Cocaine produces a spectrum of psychiatric symptoms including agitation, paranoia, anxiety, irritability, psychosis, hallucinations, delusions, violence, as well as suicidal and homicidal thinking.[27][17]
A considerable proportion of cocaine addicts exhibit hypomanic personality traits that are ego-syntonic with their pattern of cocaine abuse.[141]
Cocaine intoxication mirrors core traits of narcissism—both involve a dopamine-driven, compulsive drive for reward. Just as cocaine produces a brief high that temporarily enhances the sense of worth, narcissists rely on external admiration to feed an addiction to their self-esteem, resulting in a self-reinforcing feedback cycle.[142]
The misuse of cocaine has a high correlation with suicide.[143][144] In those who use cocaine, the risk is greatest during the withdrawal phase.[145] Cocaine use has been linked to homicide, with up to 31% of homicide victims testing positive for the drug.[27] In 1989 Fulton County, 40% of homicide victims had cocaine metabolites, especially Black and firearm victims.[146]
A 2020 study found that men with cocaine use disorder have greater difficulty identifying emotional expression in female faces, affecting relationships and suggesting a target for intervention.[147] A 2021 study found that cocaine use disorder impairs emotion recognition, especially for happiness and fear, with improvement after long-term abstinence.[148]
Depression is modestly linked to current drug use in cocaine users but does not clearly predict treatment participation or future use.[149] For people who use cocaine, stress and craving can make each other worse. This may help explain why stress can lead to relapse in people trying to stop using cocaine.[150]
Psychosis
[edit]Cocaine has a similar potential to induce temporary psychosis[151] with more than half of cocaine abusers reporting at least some psychotic symptoms at some point.[152] Typical symptoms include paranoid delusions that they are being followed and that their drug use is being watched, accompanied by hallucinations that support the delusional beliefs.[152] Delusional parasitosis with formication ('cocaine bugs') is also a fairly common symptom.[153]
Cocaine-induced psychosis shows sensitization toward the psychotic effects of the drug. This means that psychosis becomes more severe with repeated intermittent use.[152][154]
Short-term effects
[edit]Insufflating (snorting) cocaine commonly causes increased mucus production due to irritation and inflammation of the nasal passages. This irritation leads to symptoms such as a runny nose, nasal congestion, and excessive or thickened mucus.
Acute exposure to cocaine has many effects on humans, including euphoria, increases in heart rate and blood pressure, and increases in cortisol secretion from the adrenal gland.[155] In humans with acute exposure followed by continuous exposure to cocaine at a constant blood concentration, the acute tolerance to the chronotropic cardiac effects of cocaine begins after about 10 minutes, while acute tolerance to the euphoric effects of cocaine begins after about one hour.[156][157][158][159] With excessive or prolonged use, the drug can cause itching, fast heart rate, and paranoid delusions or sensations of insects crawling on the skin.[160] Cocaine can induce psychosis characterized by paranoia, impaired reality testing, hallucinations, irritability, and physical aggression. Cocaine intoxication can cause hyperawareness, hypervigilance, psychomotor agitation, and delirium. Consumption of large doses of cocaine can cause violent outbursts, especially by those with preexisting psychosis.[161] Acute exposure may induce arrhythmia, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation. Acute exposure may also lead to angina, heart attack, and congestive heart failure.[162] Cocaine overdose may cause seizures, abnormally high body temperature and a marked elevation of blood pressure, which can be life-threatening,[160] abnormal heart rhythms,[120] and death.[120] Anxiety, paranoia, and restlessness can also occur, especially during the comedown. With excessive dosage, tremors, convulsions, and increased body temperature are observed.[82]
Long-term effects
[edit]
Cocaine is highly addictive and has poor bioavailability when taken orally. Individuals often engage in repeated use by either insufflating it intranasally or converting it to crack cocaine for vaporization. Cocaine's effects last longest when insufflated (60–90 minutes),[13] but the drug itself has a short biological half-life of about 0.7–1.5 hours.[163] Repeated use raises the risk of developing "cocaine nose," referring to severe nasal tissue damage from intranasal use, as well as "crack lung," a condition involving lung tissue damage caused by inhaling crack cocaine.
Cocaine use leads to an increased risk of hemorrhagic and ischemic strokes.[26] Cocaine use also increases the risk of having a heart attack.[164]
Cocaine use also promotes the formation of blood clots.[13] This increase in blood clot formation is attributed to cocaine-associated increases in the activity of plasminogen activator inhibitor, and an increase in the number, activation, and aggregation of platelets.[13]
Cocaine constricts blood vessels, dilates pupils, and increases body temperature, heart rate, and blood pressure. It can also cause headaches and gastrointestinal complications such as abdominal pain and nausea. Chronic users may lose their appetite and experience severe malnutrition, leading to being underweight.
A 2014 study found that increased cocaine use is linked to greater cognitive impairment, particularly in working memory, while reduced or ceased use can lead to partial or full recovery of cognitive function. These findings suggest that some cocaine-related cognitive deficits are reversible, especially if use begins later in life.[165] A 2018 review found little evidence that chronic cocaine use causes widespread cognitive impairment.[166] Exposure to cocaine may lead to the breakdown of the blood–brain barrier.[167][168]
Cocaine use is frequently associated with involuntary tooth grinding, known as bruxism, which can cause dental attrition and gingivitis.[169][170] Additionally, stimulants like cocaine, methamphetamine, and even caffeine cause dehydration and dry mouth.
Addiction
[edit]Cocaine can induce tolerance after a single dose, and repeated use frequently leads to the development of addiction and prolonged craving.[156][171][172] Assessment tools like the Obsessive Compulsive Cocaine Use Scale (OCCUS) may be employed to quantify obsessive and compulsive thoughts related to cocaine consumption.[173][174]
Withdrawal symptoms include disrupted sleep, irritability, depression, and reduced ability to experience pleasure (anhedonia).[175][17] Chronic nasal use may cause destructive damage to the nasal septum, including cocaine-induced midline destructive lesions (CIMDL). Illicit cocaine is frequently adulterated with substances such as fentanyl, levamisole, or local anesthetics, increasing its toxicity.[60][176] Concurrent use with alcohol produces cocaethylene, a metabolite that significantly increases the risk of sudden death. According to the Global Burden of Disease Study, cocaine use is responsible for approximately 7,300 deaths annually.[177]
Cocaine abuse can trigger addiction-related structural neuroplasticity in the human brain, although the permanence of such changes remains uncertain.[178] Family history is a known risk factor, as relatives of cocaine users have an increased likelihood of developing cocaine addiction.[179]
A key mechanism involves the overexpression of ΔFosB in the nucleus accumbens, altering transcriptional regulation and reinforcing drug-seeking behavior.[180] Each dose of cocaine raises ΔFosB levels without a known saturation point. This elevation leads to increased brain-derived neurotrophic factor (BDNF) levels, which in turn enhance dendritic branching and spine density in neurons of the nucleus accumbens and prefrontal cortex, potentially persisting for weeks after drug cessation.[citation needed] In transgenic mice engineered to express ΔFosB in the nucleus accumbens and dorsal striatum, heightened behavioral sensitization to cocaine has been observed.[181] These mice self-administer cocaine at lower doses and display a greater propensity for relapse after withdrawal[182][183] ΔFosB also enhances sensitivity to reward by upregulating the AMPA receptor subunit GluR2[181] and downregulating the expression of dynorphin.[183]
Cocaine use has also been shown to increase DNA damage in the brains of rodents.[184][185] During subsequent DNA repair, enduring alterations in chromatin structure may arise, such as DNA methylation and methylation or acetylation of histones at the repair loci.[186] These modifications may result in lasting epigenetic "scars", which are believed to contribute to the persistent epigenetic changes observed in cocaine addiction.
Dependence and withdrawal
[edit]Cocaine dependence develops after even brief periods of regular cocaine use.[32]
About 25% of adults with attention deficit hyperactivity disorder (ADHD) use cocaine, and 10% develop a cocaine use disorder during their lifetime. Because cocaine use can worsen health outcomes, adults with ADHD should be screened for cocaine use disorder and referred for treatment if needed.[187]
Cocaine-dependent patients with high neuroticism scores are more likely to experience cocaine-induced psychotic symptoms, regardless of other drug use factors, making personality assessment important for risk identification and patient warning.[188]
Cocaine withdrawal symptoms group into two types: depressive (e.g., depression, craving, insomnia) and somatic (e.g., increased appetite, fatigue). Depressive symptoms are linked to worse outcomes like longer depression, treatment, and risky behaviors.[33]
Treatment
[edit]Because there are no medications with an approved indication for cocaine use disorder, psychosocial treatments are the current standard. Effective approaches include group and individual counseling, cognitive behavioral therapy (CBT), and motivational interviewing (MI). Contingency management (CM)—which rewards patients with vouchers for meeting treatment goals—has proven especially effective, particularly for helping patients achieve initial abstinence from cocaine.[39]

Cocaine Anonymous (CA) is a twelve-step program formed in 18 November 1982 for people who seek recovery from drug addiction. It is patterned very closely after Alcoholics Anonymous (AA), although the two groups are unaffiliated. While many CA members have been addicted to cocaine, crack, speed or similar substances, CA accepts all who desire freedom from "cocaine and all other mind-altering substances" as members.[189]
Numerous medications have been investigated for use in cocaine dependence, but as of 2015[update], none of them were considered to be effective.[38] Drugs which help to re-stabilize the glutamate system such as N-acetylcysteine have been proposed for the treatment of addiction to cocaine, nicotine, and alcohol.[190] However, none have sufficient evidence or regulatory approval for routine clinical use, so psychosocial interventions remain the mainstay of treatment.[39]
Cocaine nose
[edit]
"Cocaine nose" or "coke nose" are informal terms that refer to nose disorders resulting from repeated or chronic cocaine use.[35][191][192][193]
About 30% of people who had snorted cocaine at least 25 times but less than daily, and 47% of daily users, reported experiencing nasal irritation, crusting or scabbing, and frequent nosebleeds. Cocaine use should be considered as a potential cause of persistent or unexplained rhinitis, including in adolescent patients.[194]
Because the nose is a prominent facial feature, such visible damage often leads to embarrassment, stigma, and negative reactions from others. As a result, individuals with cocaine-induced nasal damage frequently withdraw from social activities and relationships, leading to social isolation. In many cases, this isolation is not just likely but almost inevitable, as affected individuals may feel unable to face the outside world due to the noticeable and sometimes severe changes to their appearance.[195][196]
Nose disorders associated with cocaine nose include:
- Cocaine-induced midline destructive lesions (CIMDL)[37]
- Nasal septum perforation[37]
- Palate perforation[197][198]
- Saddle nose[199]
Cocaine-induced midline destructive lesions
[edit]Cocaine-induced midline destructive lesions (CIMDL)[36] is the progressive destruction of nasal architecture with the erosion of the palate, nasal conchae, and ethmoid sinuses associated with prolonged insufflation, colloquially 'snorting', of cocaine.[37]
Chronic intranasal usage can degrade the cartilage separating the nostrils (the septum nasi), leading eventually to its complete disappearance.[200]
Causes
[edit]The cause of "cocaine nose" can be traced to the chemical process that occurs when cocaine hydrochloride is insufflated (snorted). As cocaine is absorbed through the nasal mucosa, the remaining hydrochloride component forms a dilute hydrochloric acid.[200] The short half-life of cocaine,[163] combined with binge use, may expose the nasal tissues to this acidic environment more frequently, increasing the risk of irritation and damage.
Treatment
[edit]For people with cocaine abuse, mild symptoms may resolve completely with total abstinence from cocaine, making early involvement of addiction services essential.[201]
Repair may involve rhinoplasty, which includes creating a new internal lining with nasolabial flaps and restoring support with costal cartilage grafts.[202]
In 2024, Belgian doctors report a rise in patients needing nose reconstruction due to cocaine use, which damages nasal tissue and cartilage; however, few undergo surgery because it requires at least six months of abstinence from cocaine for proper healing.[203]
Some individuals seek plastic surgery to repair or reconstruct nasal damage caused by cocaine use, although surgical outcomes can be complicated by ongoing tissue loss and poor healing. When nasal damage is too severe for reconstruction, a nose prosthesis may be used to restore appearance and quality of life.[195][196]
Overdose
[edit]

According to the European Union Drugs Agency, the estimated minimum lethal dose is 1.2 grams. However, sensitive individuals have died from as little as 30 milligrams applied to mucous membranes-an amount that is 40 times less than the minimum lethal dose. In contrast, addicts may tolerate doses as high as 5 grams per day.[14]
Cocaine can be snorted, swallowed, injected, or smoked. Most deaths due to cocaine are accidental but may also be the result of body packing or stuffing with rupture in the gastrointestinal tract. Alcohol impairment increases the likelihood of risk-taking behaviors and susceptibility to peer pressure, and also raises the risk of overdose due to the formation of cocaethylene (see the alcohol section).
Use of cocaine causes abnormally fast heart rhythms and a marked elevation of blood pressure (hypertension), which can be life-threatening. This can lead to death from acute myocardial infarction, acute respiratory failure (i.e., hypoxemia, with or without hypercapnia), stroke, cerebral hemorrhage, and sudden cardiac arrest.[205] Overdose can also cause acute hepatotoxicity—typically due to toxic metabolites—though most cases resolve quickly; however, fatal outcomes from multiple organ dysfunction syndrome are possible, and there is no specific antidote.[206] Cocaine overdose may result in hyperthermia as stimulation and increased muscular activity cause greater heat production. Heat loss is also inhibited by the cocaine-induced vasoconstriction.
In 2024, drug-related deaths in England and Wales reached their highest level in three decades, with a notable increase in fatalities involving cocaine and experts urging urgent government intervention to address the crisis. Martin Powell, from the charity Transform, which campaigns for the legal regulation of drugs, suggested that the recent rise in cocaine-related deaths in the UK may be due to the increased purity of cocaine, leading users to consume it more frequently and alongside other substances.[207]
Interactions
[edit]Alcohol
[edit]Alcohol interacts with cocaine in vivo to produce cocaethylene, another psychoactive substance which may be substantially more cardiotoxic than either cocaine or alcohol by themselves.[208][209] In 2024, a systematic review of human studies concluded that, despite some inconsistencies in the findings, the co-use of cocaine and alcohol poses a significantly greater risk of cardiovascular fatalities compared to cocaine use alone. This elevated risk is largely attributed to the formation of cocaethylene, a unique and toxic metabolite produced only when both substances are consumed together. Cocaethylene is associated with an 18- to 25-fold increased risk of sudden death, as well as a higher incidence of myocardial injury and cardiac arrest, underscoring the serious health risks of simultaneous cocaine and alcohol use.[210]
MAOIs
[edit]Monoamine oxidase inhibitors (MAOIs) should not be combined with other psychoactive substances (antidepressants, painkillers, stimulants, including prescribed, OTC and illegally acquired drugs, etc.) except under expert care.[citation needed]
Opioids
[edit]The opioid epidemic now involves more overdose deaths with both opioids and cocaine, especially among non-Hispanic Blacks who are twice as likely to die from combined opioid-stimulant overdoses compared to non-Hispanic whites. Cocaine-related deaths in Blacks are similar to opioid deaths in whites. Risk factors include young age, education, urban living, mental disorders, and stress. It remains unclear if co-use is intentional. Recent studies expand focus beyond heroin to all opioids, reflecting changing overdose patterns.[211]
Pharmacology
[edit]Pharmacokinetics
[edit]The extent of absorption of cocaine into the circulatory system after nasal insufflation is similar to that after oral ingestion. The rate of absorption after nasal insufflation is limited by cocaine-induced vasoconstriction of capillaries in the nasal mucosa. Onset of absorption after oral ingestion is delayed because cocaine is a weak base with a pKa of 8.6, and is thus in an ionized form that is poorly absorbed from the gastric acid and easily absorbed from the alkaline duodenum.[12] The rate and extent of absorption from inhalation of cocaine is similar or greater than with intravenous injection, as inhalation provides access directly to the capillary bed. The delay in absorption after oral ingestion may account for the popular belief that cocaine bioavailability from the stomach is lower than after insufflation. Compared with ingestion, the faster absorption of insufflated cocaine results in quicker attainment of maximum drug effects. Snorting cocaine produces maximum physiological effects within 40 minutes and maximum psychotropic effects within 20 minutes. Physiological and psychotropic effects from nasally insufflated cocaine are sustained for approximately 40–60 minutes after the peak effects are attained.[212]
Cocaine crosses the blood–brain barrier via both a proton-coupled organic cation antiporter[213][214] and (to a lesser extent) via passive diffusion across cell membranes.[215] As of September 2022, the gene or genes encoding the human proton-organic cation antiporter had not been identified.[216]
Cocaine has a short elimination half-life of 0.7–1.5 hours and is extensively metabolized by plasma esterases and also by liver cholinesterases, with only about 1% excreted unchanged in the urine.[13] The metabolism is dominated by hydrolytic ester cleavage, so the eliminated metabolites consist mostly of benzoylecgonine (BE), the major metabolite, and other metabolites in lesser amounts such as ecgonine methyl ester (EME) and ecgonine.[217][13] Further minor metabolites of cocaine include norcocaine, p-hydroxycocaine, m-hydroxycocaine, p-hydroxybenzoylecgonine (pOHBE), and m-hydroxybenzoylecgonine.[218]
Depending on liver and kidney functions, cocaine metabolites are detectable in urine between three and eight days. Generally speaking benzoylecgonine is eliminated from someone's urine between three and five days. In urine from heavy cocaine users, benzoylecgonine can be detected within four hours after intake and in concentrations greater than 150 ng/mL for up to eight days later.[219]
Detection in the body
[edit]Body fluids
[edit]Cocaine and its major metabolites may be quantified in blood, plasma, or urine to monitor for use, confirm a diagnosis of poisoning, or assist in the forensic investigation of a traffic or other criminal violation or sudden death. Most commercial cocaine immunoassay screening tests cross-react appreciably with the major cocaine metabolites, but chromatographic techniques can easily distinguish and separately measure each of these substances. When interpreting the results of a test, it is important to consider the cocaine usage history of the individual, since a chronic user can develop tolerance to doses that would incapacitate a cocaine-naive individual, and the chronic user often has high baseline values of the metabolites in his system. Cautious interpretation of testing results may allow a distinction between passive or active usage, and between smoking versus other routes of administration.[220]
Hair
[edit]Hair analysis can detect cocaine metabolites in regular users until after the sections of hair grown during the period of cocaine use are cut or fall out.[221]
Pharmacodynamics
[edit]Cocaine acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[7][24] Cocaine increases levels of serotonin, norepinephrine, and dopamine in the synaptic cleft, leading to heightened post-synaptic activation, with dopamine contributing to euphoria and arousal, and the other monoamines enhancing additional effects.[7][222][223][224]
The pharmacodynamics of cocaine involve the complex relationships of neurotransmitters (inhibiting monoamine uptake in rats with ratios of about: serotonin:dopamine = 2:3, serotonin:norepinephrine = 2:5).[225][17] The most extensively studied effect of cocaine on the central nervous system is the blockade of the dopamine transporter protein. Dopamine neurotransmitter released during neural signaling is normally recycled via the transporter; i.e., the transporter binds the transmitter and pumps it out of the synaptic cleft back into the presynaptic neuron, where it is taken up into storage vesicles. Cocaine binds tightly at the dopamine transporter forming a complex that blocks the transporter's function. The dopamine transporter can no longer perform its reuptake function, and thus dopamine accumulates in the synaptic cleft. The increased concentration of dopamine in the synapse activates post-synaptic dopamine receptors, which makes the drug rewarding and promotes the compulsive use of cocaine.[226]
Cocaine affects certain serotonin (5-HT) receptors; in particular, it has been shown to antagonize the 5-HT3 receptor, which is a ligand-gated ion channel. An overabundance of 5-HT3 receptors is reported in cocaine-conditioned rats, though 5-HT3's role is unclear.[227] The 5-HT2 receptor (particularly the subtypes 5-HT2A, 5-HT2B and 5-HT2C) are involved in the locomotor-activating effects of cocaine.[228]
Cocaine has been demonstrated to bind as to directly stabilize the DAT transporter on the open outward-facing conformation. Further, cocaine binds in such a way as to inhibit a hydrogen bond innate to DAT. Cocaine's binding properties are such that it attaches so this hydrogen bond will not form and is blocked from formation due to the tightly locked orientation of the cocaine molecule. Research studies have suggested that the affinity for the transporter is not what is involved in the habituation of the substance so much as the conformation and binding properties to where and how on the transporter the molecule binds.[229]
Conflicting findings have challenged the widely accepted view that cocaine functions solely as a reuptake inhibitor. To induce euphoria an intravenous dose of 0.3-0.6 mg/kg of cocaine is required, which blocks 66-70% of DAT in the brain.[230] Re-administering cocaine beyond this threshold does not significantly increase DAT occupancy but still results in an increase of euphoria which cannot be explained by reuptake inhibition alone. This discrepancy is not shared with other dopamine reuptake inhibitors like bupropion, sibutramine, mazindol or tesofensine, which have similar or higher potencies than cocaine as dopamine reuptake inhibitors. Furthermore, a similar response-occupancy discrepancy has been observed with methylphenidate, which also stabilizes the dopamine transporter in an open outward-facing conformation.[231][232][233] These findings have evoked a hypothesis that cocaine may also function as a so-called "DAT inverse agonist" or "negative allosteric modifier of DAT" resulting in dopamine transporter reversal, and subsequent dopamine release into the synaptic cleft from the axon terminal in a manner similar to but distinct from amphetamines.[231]
Sigma receptors are affected by cocaine, as cocaine functions as a sigma ligand agonist.[234] Further specific receptors it has been demonstrated to function on are NMDA and the D1 dopamine receptor.[235]
Cocaine also blocks sodium channels, thereby interfering with the propagation of action potentials;[236][120] thus, like lignocaine and novocaine, it acts as a local anesthetic. It also functions on the binding sites to the dopamine and serotonin sodium dependent transport area as targets as separate mechanisms from its reuptake of those transporters; unique to its local anesthetic value which makes it in a class of functionality different from both its own derived phenyltropanes analogues which have that removed. In addition to this, cocaine has some target binding to the site of the κ-opioid receptor.[237][unreliable medical source?] Cocaine also causes vasoconstriction, thus reducing bleeding during minor surgical procedures. Recent research points to an important role of circadian mechanisms[238] and clock genes[239] in behavioral actions of cocaine.
Cocaine is known to suppress hunger and appetite by increasing co-localization of sigma σ1R receptors and ghrelin GHS-R1a cell surface receptors, thereby increasing ghrelin-mediated signaling of satiety[240] and possibly via other effects on appetitive hormones.[241]
Cocaine effects, further, are shown to be potentiated for the user when used in conjunction with new surroundings and stimuli, and otherwise novel environs.[242]
Chemistry
[edit]Forms
[edit]

In its purest form, cocaine is a white, pearly powder. As a tropane alkaloid, cocaine is a weak base and readily forms salts when combined with acids. The most commonly encountered form is the hydrochloride (HCl) salt, although other salts such as the sulfate (SO42−) and nitrate (NO3−) are occasionally observed. The solubility of these salts varies depending on their polarity; the hydrochloride salt is polar and highly soluble in water.[243]
Synthesis
[edit]Total synthesis
[edit]The first structure elucidation and total synthesis of the cocaine molecule was accomplished by Richard Willstätter in 1898.[244] Willstätter's synthesis involved constructing the cocaine structure from simpler precursors, notably via the intermediate tropinone. Subsequent significant contributions to understanding the synthetic pathway and stereochemistry were made by Robert Robinson and Edward Leete.
Cocaine contains four chiral centers (1R, 2R, 3S, and 5S), two of which are configurationally dependent, resulting in eight possible stereoisomers. The formation of inactive stereoisomers, along with various synthetic by-products, limits both the yield and purity of the final product.[245][246]
Although the chemical synthesis of cocaine is technically feasible, it is generally considered impractical due to its high cost, low efficiency, and challenges in stereoselective synthesis compared to extraction from natural plant sources. While domestic clandestine laboratories could theoretically reduce reliance on offshore production and international smuggling—as seen with illicit methamphetamine—manufacture and synthetic production of cocaine remains rare. Large-scale commercial synthesis has not been explored.[247]
Biosynthesis
[edit]The biosynthesis of cocaine is the natural metabolic process by which the coca plant (Erythroxylum species) produces cocaine, a tropane alkaloid, through a multi-step enzymatically catalyzed pathway beginning with ornithine or arginine and culminating in the formation of the cocaine metabolite benzoylecgonine.
Large-scale biosynthesis of cocaine is unexplored.[247]
The biosynthesis of cocaine has long attracted the attention of biochemists and organic chemists. This interest is partly motivated by the strong physiological effects of cocaine, but a further incentive was the unusual bicyclic structure of the molecule. The biosynthesis can be viewed as occurring in two phases, one phase leading to the N-methylpyrrolinium ring, which is preserved in the final product. The second phase incorporates a C4 unit with formation of the bicyclic tropane core.[248]
GMO synthesis
[edit]In 2022, a GMO produced N. benthamiana were discovered that were able to produce 25% of the amount of cocaine found in a coca plant.[249]
However, since N. benthamiana also naturally contains nicotine, separating the cocaine from nicotine and related alkaloids would be challenging.
Field analysis
[edit]

Personal cards-including ID cards and driver's licenses-are frequently swabbed by inspectors to detect drug residue, as these items are commonly used to prepare lines of cocaine. Swabbing can reveal traces of cocaine or other illicit substances, providing evidence of recent drug handling or use. This practice may be employed during security checks at border crossings.
A Newsbeat investigation found that "cocaine torches" used by UK police to detect cocaine use are ineffective on typical street cocaine, as independent lab tests showed they fail to make the drug fluoresce. Experts and drug charities criticized the devices, warning they can give false positives and waste resources, while police forces defended their use as a deterrent. The manufacturer says the torches only work on much purer forms of cocaine than are found on the street.[250][251]
Cocaine may be detected by law enforcement using the Scott reagent. The test can easily generate false positives for common substances and must be confirmed with a laboratory test.[252][253]
Approximate cocaine purity can be determined using 1 mL 2% cupric sulfate pentahydrate in dilute HCl, 1 mL 2% potassium thiocyanate and 2 mL of chloroform. The shade of brown shown by the chloroform is proportional to the cocaine content. This test is not cross sensitive to heroin, methamphetamine, benzocaine, procaine and a number of other drugs but other chemicals could cause false positives.[254]
Society and culture
[edit]Both the pharmaceutical supply chain and the illicit supply chain obtain cocaine from coca cultivated in Latin America, but they operate under very different controls and oversight. In Peru, for example, legal coca cultivation is monopolized by the state company National Coca Company (ENACO), yet approximately 90% of coca leaves produced in the country are diverted to illegal actors for cocaine manufacturing.[255] As a result, these illicit coca crops are a primary target of ongoing government-led coca eradication efforts.[256]
Cocaine is prohibited in competition for athletes by the World Anti-Doping Agency (WADA), which lists it as a stimulant on its International Standard for the Prohibited List.[257]: 6
Street names
[edit]Cocaine is sometimes referred to on the street as blow, coca, coke, crank, flake, snow, or soda cot. Slang terms for free base cocaine include crack or rock.[258]
Fishscale cocaine, from fish + scale, is named for its shiny, yellowish flakes that resemble fish scales—distinct from the dull white appearance of standard cocaine powder.
Legal status
[edit]
The production, distribution, and sale of cocaine products is restricted (and illegal in most contexts) in most countries as regulated by the Single Convention on Narcotic Drugs, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. In the United States the manufacture, importation, possession, and distribution of cocaine are additionally regulated by the 1970 Controlled Substances Act.
Some countries, such as Bolivia, Colombia, and Peru, permit the cultivation of coca leaf for traditional consumption by the local indigenous population, but nevertheless, prohibit the production, sale, and consumption of cocaine.[259] The provisions as to how much a coca farmer can yield annually is protected by laws such as the Bolivian Cato accord.[260] In addition, some parts of Europe, the United States, and Australia allow processed cocaine for medicinal uses only.
Australia
[edit]Cocaine is a Schedule 8 controlled drug in Australia under the Poisons Standard.[261] It is the second most popular illicit recreational drug in Australia behind cannabis.[262]
In Western Australia under the Misuse of Drugs Act 1981, 4.0g of cocaine is the amount of prohibited drugs determining a court of trial, 2.0g is the amount of cocaine required for the presumption of intention to sell or supply, and 28.0g is the amount of cocaine required for purposes of drug trafficking.[263]
United States
[edit]
The US federal government instituted a national drug labelling requirement for cocaine and cocaine-containing products through the Pure Food and Drug Act of 1906.[264]: 37 The next important federal regulation was the Harrison Narcotics Tax Act of 1914. While this act is often seen as the start of prohibition, the act itself was not actually a prohibition on cocaine, but instead it set up a regulatory and licensing regime.[265] The Harrison Act did not recognize addiction as a treatable condition and therefore the therapeutic use of cocaine, heroin, or morphine to such individuals was outlawed – leading a 1915 editorial in the journal American Medicine to remark that the addict "is denied the medical care he urgently needs, open, above-board sources from which he formerly obtained his drug supply are closed to him, and he is driven to the underworld where he can get his drug, but of course, surreptitiously and in violation of the law."[266] The Harrison Act left manufacturers of cocaine untouched so long as they met certain purity and labeling standards.[264]: 40 Despite that cocaine was typically illegal to sell and legal outlets were rarer, the quantities of legal cocaine produced declined very little.[264]: 40 Legal cocaine quantities did not decrease until the Jones–Miller Act of 1922 put serious restrictions on cocaine manufactures.[264]: 40
Before the early 1900s, newspapers primarily portrayed addiction (rather than violence or crime) as the main problem caused by cocaine use, and depicted cocaine users as upper or middle class White people. In 1914, The New York Times published an article titled "Negro Cocaine 'Fiends' Are a New Southern Menace," portraying Black people who used cocaine as dangerous and able to withstand wounds that would normally be fatal.[267] The Anti-Drug Abuse Act of 1986 mandated the same prison sentences for distributing 500 grams of powdered cocaine and just 5 grams of crack cocaine.[268] In the National Survey on Drug Use and Health, white respondents reported a higher rate of powdered cocaine use, and Black respondents reported a higher rate of crack cocaine use.[269]
Prevalence and trends
[edit]Cocaine production, seizures, and use all reached record levels in 2023, making it the world's fastest-growing illicit drug market. Seizures rose by 68% from 2019 to 2023, while the number of users increased from 17 million in 2013 to 25 million in 2023, according to the UNODC World Drug Report 2025.[50]
The report further states that Western Europe's cocaine market is rapidly expanding, resulting in increased violence driven by traffickers, including organized criminal groups from the Western Balkans. Concurrently, record levels of cocaine production have enabled traffickers to enter new markets across Asia and Africa, reflecting the expanding global reach of cocaine trafficking.[48]
The U.S. is the world's largest consumer of cocaine,[270] while South America, as a continent, ranks third in terms of consumer market size.[18] Europe ranks cocaine as the second most commonly used illicit drug.[271]
Cocaine is among the most widely consumed recreational stimulants worldwide.[25]
Impact
[edit]Impact of illicit cocaine
[edit]Impact on impoverished communities
[edit]In countries where cocaine is illicitly produced, an intermediate product known as cocaine paste—often referred to as "poor man's cocaine"—is frequently smoked in impoverished communities. This substance is favored in these areas primarily because it is inexpensive and more accessible than refined cocaine. However, the use of cocaine paste poses severe health risks. During its production, various toxic chemicals are used to extract coca alkaloids from the coca leaves. Many of these hazardous substances, such as solvents and acids, remain in the paste after processing. When the paste is smoked, individuals are exposed not only to the addictive effects of the drug itself but also to the dangerous residual chemicals, which can cause significant harm to the lungs, nervous system, and overall health. This combination of affordability, accessibility, and toxicity makes cocaine paste particularly damaging to vulnerable populations in cocaine-producing regions.[23][100][101][102]
Environmental impact
[edit]Most of the world's cocaine is produced in South America, particularly in the Andean region.[272] The environmental destruction caused by the production of cocaine has been well documented, with reports made the UN and other government bodies.[273] Due to the illegal nature of coca production, farmers make little effort in soil conservation and sustainability practices as seen in the high mobility and short life of coca plots in Colombia.[272]
One of the major implications of cocaine production is deforestation as large areas of forest are cleared for coca cultivation. The UNODC approximated that 97,622 hectares of primary forest were cleared for coca cultivation during 2001–2004 in the Andean region.[272] This further causes habitat destruction, especially in biodiversity hotspots, areas rich in a variety of species. Such areas are chosen for coca cultivation due to their remote locations, minimising chances of detection.[274] Deforestation impacts soil erosion which further inhibits the survival of native species.[272]
The use of pesticides can also severely affect the environment. Farmers are able to use unregulated and highly toxic pesticides due to the clandestine nature of drug production.[274] The use of such pesticides can have both direct and indirect effects on the ecosystem. Where lethal levels of exposure directly cause the death of fauna, which is further carried up the food chain where secondary feeders who consume the poisoned animals are also impacted. Furthermore, non-lethal levels of exposure can also cause weaker immune system development and neurological issues, further increasing mortality rates.[274]
Impact of illicit cocaine trade
[edit]Cocaine is extremely expensive on the black market, with prices rising sharply at each distribution level—often more than its weight in gold.[275]
Latin America
[edit]Drug war policies in Latin America and the Caribbean have led to more violence, higher incarceration rates, health crises, and deeper poverty, while undermining trust in institutions and worsening inequality. There is increasing support for shifting toward drug policies that focus on sustainable development and human rights instead of punitive measures.[49]
West Africa
[edit]Cocaine trafficking in West Africa has become closely linked with the activities of several terrorist organizations.[276][277][278]
Impact of enforcement
[edit]Impact of coca eradication
[edit]In December 2000, Dutch journalist Marjon van Royen found that "because the chemical is sprayed in Colombia from planes on inhabited areas, there have been consistent health complaints [in humans]. Burning eyes, dizziness and respiratory problems being most frequently reported." In some areas, 80 percent of the children of the indigenous community fell sick with skin rashes, fever, diarrhoea and eye infections.[279] Because the glyphosate is sprayed from the air, there is a much higher chance of human error when spraying suspected illegal coca plantations. In many cases the wrong fields are sprayed, resulting in not only a total loss of the farmer's crop- but the loss of that field altogether as nothing will grow where the herbicide has been sprayed.[280] Though official documentation of the health effects of glyphosate spraying in Colombia are virtually non-existent, neighbouring Ecuador has conducted studies to determine the cause of mysterious illnesses amongst people living along the border of Colombia and has since demanded that no aerial sprayings occur within 10 km of the border because of the damages caused to the people, animals and environment in that area.[280] In 2015, Colombia announced a ban on using glyphosate in these programs due to concerns about human toxicity of the chemical.[281]
Impact of interdiction
[edit]The Consolidated Counterdrug Database (CCDB) is a U.S. government dataset created in the 1990s that compiles vetted data on cocaine trafficking and seizures in the Western Hemisphere "transit zone," involving 26 U.S. agencies and 20 foreign partners. It provides a highly reliable, conservative record of cocaine movements and interdiction efforts, revealing that despite large seizures, interdiction captures only a small fraction of trafficking events and has minimal impact on U.S. cocaine prices. The CCDB challenges optimistic views of drug interdiction effectiveness and underscores the need for new policy approaches, yet remains underutilized in research despite being unclassified.[282]
Research
[edit]Cocaine haptens are chemically modified derivatives of cocaine that retain key immunogenic features, allowing them to be attached to carrier proteins such as keyhole limpet hemocyanin or bovine serum albumin. This enables the immune system to recognize cocaine and produce anti-cocaine antibodies, which can bind cocaine in the bloodstream and prevent it from reaching the brain, thereby blocking its psychoactive effects.[283][284][285]
The cocaine esterase enzyme and redesigned versions of it have been studied as a potential treatment for cocaine addiction in humans.[286]
Coca tea has been explored as a supportive treatment for cocaine dependence. A study in Lima, Peru, found that using coca leaf infusion along with counseling reduced relapse rates and significantly increased the duration of abstinence among addicted individuals, suggesting that this approach may help prevent relapse during treatment.[287]
Recent research has also examined the use of prescription psychostimulants for cocaine dependence, following the Self-Medication Hypothesis. This hypothesis suggests that some individuals use cocaine to address underlying neurochemical or psychological issues. While some studies indicate that psychostimulant therapy may reduce cocaine use and cravings, the evidence is mixed and further research is needed.[288]
In animal studies, nicotine exposure in mice increases the likelihood of later cocaine use, with clear molecular changes in the brain.[289] These findings mirror human epidemiological data showing a link between nicotine use and increased risk of later cannabis and cocaine use, as well as other substances.[290][291] Similarly, in rats, alcohol consumption raises the probability of later cocaine addiction and is associated with changes in the brain's reward system.[292][293] Human studies also show that alcohol use increases the risk of transitioning from cocaine use to addiction.[294][295]
Experimentally, cocaine injections can be delivered to animals such as fruit flies to study the mechanisms of cocaine addiction.[296]
Cocaine vaccines
[edit]Calixcoca
[edit]Calixcoca is an experimental vaccine to treat cocaine and crack cocaine addiction. It has been in development since 2015 by the Federal University of Minas Gerais (UFMG) in Brazil.[297]
TA-CD
[edit]TA-CD is a vaccine developed by the Xenova Group and designed to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.[298]
History
[edit]Coca leaves have been used by indigenous South Americans for thousands of years, both as a stimulant and for medicinal purposes.[299]
When the Spanish arrived in South America, they initially banned coca but soon legalized and taxed it after seeing its importance to local labor.[300] The active ingredient, cocaine, was first isolated in 1855 by Friedrich Gaedcke and later refined by Albert Niemann, who named it "cocaine."[301][302][303] In the late 1800s, cocaine became popular in Western medicine as a local anesthetic and was widely used in various products, including drinks and remedies.[304] and James Leonard Corning demonstrated peridural anesthesia.[305] However, due to its toxic effects and potential for abuse, safer alternatives eventually replaced it in medical practice.[19]
Large-scale coca cultivation and cocaine production occurred in Taiwan Asia, in Taiwan (then known as Formosa) and Java (today part of Indonesia) before World War II.[53][54]
Since the 1980s, the cocaine trade was dominated by centralized, hierarchical drug cartels such as Medellín and Cali, along with their successors and early FARC factions. By the early 2000s, this model fragmented into a diverse network of global trafficking links, allowing South American cocaine production to easily supply markets in Europe, Africa, Asia, and Oceania through various routes.[306]
Etymology
[edit]See also
[edit]- Cocaine reverse ester
- Cocaine and amphetamine regulated transcript
- MDMA – also acts, to a lesser extent, as an SNDRI like cocaine
References
[edit]- ^ Nordegren T (2002). The A-Z Encyclopedia of Alcohol and Drug Abuse. Universal-Publishers. p. 461. ISBN 978-1-58112-404-0. Archived from the original on 8 July 2024. Retrieved 3 September 2020.
- ^ a b c "Goprelto – cocaine hydrochloride solution". DailyMed. 3 January 2020. Archived from the original on 30 July 2020. Retrieved 30 April 2020.
- ^ a b c "Numbrino – cocaine hydrochloride nasal solution". DailyMed. 28 February 2020. Archived from the original on 30 July 2020. Retrieved 30 April 2020.
- ^ Ghodse H (2010). Ghodse's Drugs and Addictive Behaviour: A Guide to Treatment (4 ed.). Cambridge University Press. p. 91. ISBN 978-1-139-48567-8. Archived from the original on 10 September 2017.
- ^ Introduction to Pharmacology (3 ed.). Abingdon: CRC Press. 2007. pp. 222–223. ISBN 978-1-4200-4742-4. Archived from the original on 10 September 2017.
- ^ Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, et al. (April 2001). "Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference". Proceedings of the National Academy of Sciences of the United States of America. 98 (9): 5300–5305. Bibcode:2001PNAS...98.5300S. doi:10.1073/pnas.091039298. PMC 33204. PMID 11320258.
- ^ a b c d Azizi SA (April 2022). "Monoamines: Dopamine, Norepinephrine, and Serotonin, Beyond Modulation, "Switches" That Alter the State of Target Networks". The Neuroscientist. 28 (2): 121–143. doi:10.1177/1073858420974336. PMID 33292070. S2CID 228080727.
- ^ "DEA / Drug Scheduling". www.dea.gov. Archived from the original on 9 August 2017. Retrieved 7 August 2017.
- ^ a b Fattinger K, Benowitz NL, Jones RT, Verotta D (July 2000). "Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine". European Journal of Clinical Pharmacology. 56 (4): 305–10. doi:10.1007/s002280000147. PMID 10954344. S2CID 20708443.
- ^ Barnett G, Hawks R, Resnick R (1981). "Cocaine pharmacokinetics in humans". Journal of Ethnopharmacology. 3 (2–3): 353–66. doi:10.1016/0378-8741(81)90063-5. PMID 7242115.
- ^ Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, Cook CE (1989). "Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking". Drug Metabolism and Disposition. 17 (2): 153–9. doi:10.1016/S0090-9556(25)08737-9. PMID 2565204.
- ^ a b Wilkinson P, Van Dyke C, Jatlow P, Barash P, Byck R (March 1980). "Intranasal and oral cocaine kinetics". Clinical Pharmacology and Therapeutics. 27 (3): 386–94. doi:10.1038/clpt.1980.52. PMID 7357795. S2CID 29851205.
- ^ a b c d e f g h i j k l Zimmerman JL (October 2012). "Cocaine intoxication". Critical Care Clinics. 28 (4): 517–26. doi:10.1016/j.ccc.2012.07.003. PMID 22998988.
- ^ a b "Cocaine and crack drug profile | www.euda.europa.eu". www.euda.europa.eu.
- ^ "Cocaine - Alcohol and Drug Foundation". adf.org.au.
- ^ "The identification of coca (Erythroxylum species)". Botanical Journal of the Linnean Society. doi:10.1111/j.1095-8339.1982.tb00368.x.
- ^ a b c d e f g Pomara C, Cassano T, D'Errico S, Bello S, Romano AD, Riezzo I, et al. (2012). "Data available on the extent of cocaine use and dependence: biochemistry, pharmacologic effects and global burden of disease of cocaine abusers". Current Medicinal Chemistry. 19 (33): 5647–57. doi:10.2174/092986712803988811. PMID 22856655.
- ^ a b c d "Coca Cultivation in the Andean Region" (PDF). UNODC. June 2006.
- ^ a b c Latorre F, Klimek L (January 1999). "Does cocaine still have a role in nasal surgery?". Drug Safety. 20 (1): 9–13. doi:10.2165/00002018-199920010-00002. PMID 9935273. S2CID 40598106.
- ^ a b Bremner F (2019). "Apraclonidine Is Better Than Cocaine for Detection of Horner Syndrome". Frontiers in Neurology. 10 55. doi:10.3389/fneur.2019.00055. PMC 6371044. PMID 30804875.
- ^ a b c d Armbuster YC, Banas BN, Feickert KD, England SE, Moyer EJ, Christie EL, et al. (December 2021). "Decline and Pronounced Regional Disparities in Medical Cocaine Usage in the United States". The Journal of Pharmacy Technology. 37 (6): 278–285. doi:10.1177/87551225211035563. PMC 8592245. PMID 34790964.
- ^ a b "WHO Model List of Essential Medicines - 23rd list, 2023". www.who.int.
- ^ a b Cortés E, Metaal P. Smokable cocaine markets in Latin America and the Caribbean (PDF).
- ^ a b Cheng MH, Block E, Hu F, Cobanoglu MC, Sorkin A, Bahar I (2015). "Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding". Frontiers in Neurology. 6: 134. doi:10.3389/fneur.2015.00134. PMC 4460958. PMID 26106364.
- ^ a b Roque Bravo R, Faria AC, Brito-da-Costa AM, Carmo H, Mladěnka P, Dias da Silva D, et al. (April 2022). "Cocaine: An Updated Overview on Chemistry, Detection, Biokinetics, and Pharmacotoxicological Aspects including Abuse Pattern". Toxins. 14 (4): 278. doi:10.3390/toxins14040278. PMC 9032145. PMID 35448887.
- ^ a b c Sordo L, Indave BI, Barrio G, Degenhardt L, de la Fuente L, Bravo MJ (September 2014). "Cocaine use and risk of stroke: a systematic review". Drug and Alcohol Dependence (Systematic Review). 142: 1–13. doi:10.1016/j.drugalcdep.2014.06.041. PMID 25066468.
- ^ a b c Morton WA (August 1999). "Cocaine and Psychiatric Symptoms". Primary Care Companion to the Journal of Clinical Psychiatry. 1 (4): 109–113. doi:10.4088/pcc.v01n0403. PMC 181074. PMID 15014683.
- ^ a b Buckingham-Howes S, Berger SS, Scaletti LA, Black MM (2013). "Systematic Review of Prenatal Cocaine Exposure and Adolescent Development". Pediatrics. 131 (6): e1917 – e1936. doi:10.1542/peds.2012-0945. PMC 3666107. PMID 23713107.
- ^ a b Lambert B, Bauer C (November 2012). "Developmental and behavioral consequences of prenatal cocaine exposure: a review". Journal of Perinatology. 32 (11): 819–828. doi:10.1038/jp.2012.90. PMC 4143247. PMID 22791278.
- ^ a b McCarthy DM, Kabir ZD, Bhide PG, Kosofsky BE (2014). "Effects of prenatal exposure to cocaine on brain structure and function". Progress in Brain Research. Vol. 211. pp. 277–289. doi:10.1016/B978-0-444-63425-2.00012-X. ISBN 978-0-444-63425-2. PMID 24968785.
- ^ a b Eiden RD, McAuliffe S, Kachadourian L, Coles C, Colder C, Schuetze P (January 2009). "Effects of prenatal cocaine exposure on infant reactivity and regulation". Neurotoxicology and Teratology. 31 (1): 60–68. Bibcode:2009NTxT...31...60E. doi:10.1016/j.ntt.2008.08.005. PMC 2631277. PMID 18822371.
- ^ a b Gawin FH, Ellinwood EH (1989). "Cocaine dependence". Annual Review of Medicine. 40: 149–61. doi:10.1146/annurev.me.40.020189.001053. PMID 2658744.
- ^ a b Sofuoglu M, Dudish-Poulsen S, Poling J, Mooney M, Hatsukami DK (July 2005). "The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users". Addictive Behaviors. 30 (6): 1125–1134. doi:10.1016/j.addbeh.2004.10.010. PMID 15925122.
- ^ a b c Clare K, Park K, Pan Y, Lejuez CW, Volkow ND, Du C (2024). "Neurovascular effects of cocaine: relevance to addiction". Frontiers in Pharmacology. 15 1357422. doi:10.3389/fphar.2024.1357422. PMC 10917943. PMID 38455961.
- ^ a b Berberi A, Azar E (2024). "Oral Rehabilitation for a Patient with Cocaine-Induced Midline Destructive Lesions". Case Reports in Otolaryngology. 2024 7109261. doi:10.1155/2024/7109261. PMC 11208820. PMID 38939732.
- ^ a b Nitro L, Pipolo C, Fadda GL, Allevi F, Borgione M, Cavallo G, et al. (July 2022). "Distribution of cocaine-induced midline destructive lesions: systematic review and classification". European Archives of Oto-Rhino-Laryngology. 279 (7): 3257–3267. doi:10.1007/s00405-022-07290-1. PMC 9130192. PMID 35138441.
- ^ a b c d Di Cosola M, Ambrosino M, Limongelli L, Favia G, Santarelli A, Cortelazzi R, et al. (July 2021). "Cocaine-Induced Midline Destructive Lesions (CIMDL): A Real Challenge in Diagnosis". International Journal of Environmental Research and Public Health. 18 (15): 7831. doi:10.3390/ijerph18157831. PMC 8345435. PMID 34360121.
- ^ a b Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. (April 2015). Minozzi S (ed.). "Anticonvulsants for cocaine dependence". The Cochrane Database of Systematic Reviews (Systematic Review & Meta-Analysis). 2015 (4) CD006754. doi:10.1002/14651858.CD006754.pub4. PMC 8812341. PMID 25882271.
- ^ a b c Kampman KM (October 2019). "The treatment of cocaine use disorder". Science Advances. 5 (10) eaax1532. Bibcode:2019SciA....5.1532K. doi:10.1126/sciadv.aax1532. PMC 6795516. PMID 31663022.
- ^ a b Buchanan JA, Oyer RJ, Patel NR, Jacquet GA, Bornikova L, Thienelt C, et al. (June 2010). "A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole". Journal of Medical Toxicology. 6 (2): 160–164. doi:10.1007/s13181-010-0060-3. PMC 3550277. PMID 20358411.
- ^ a b Vonmoos M, Hirsiger S, Preller KH, Hulka LM, Allemann D, Herdener M, et al. (October 2018). "Cognitive and neuroanatomical impairments associated with chronic exposure to levamisole-contaminated cocaine". Translational Psychiatry. 8 (1) 235. doi:10.1038/s41398-018-0279-3. PMC 6204136. PMID 30368522.
- ^ a b c Gill H, Trinh D, Anderson DJ, Li N, Madenberg D (August 2021). "Cocaine and Levamisole Induced Vasculitis". Cureus. 13 (8) e17192. doi:10.7759/cureus.17192. PMC 8439268. PMID 34548986.
- ^ a b c Cascio MJ, Jen KY (January 2018). "Cocaine/levamisole-associated autoimmune syndrome: a disease of neutrophil-mediated autoimmunity". Current Opinion in Hematology. 25 (1): 29–36. doi:10.1097/MOH.0000000000000393. PMID 29211697.
- ^ Murillo-Sandoval PJ, Sesnie SE, Ordoñez Armas ME, Magliocca N, Tellman B, Devine JA, et al. (1 October 2024). "Central America's agro-ecological suitability for cultivating coca, Erythroxylum spp". Environmental Research Letters. 19 (10): 104068. Bibcode:2024ERL....19j4068M. doi:10.1088/1748-9326/ad7276.
- ^ "Plantaciones, laboratorios y narcorutas de coca en Honduras". www.elheraldo.hn (in Spanish).
- ^ Papadovassilakis A, Voss G (10 February 2023). "Guatemala registra récord en producción de coca, pero no de cocaína". InSight Crime (in European Spanish).
- ^ "Police find half a million coca plants in Southern Belize". Belize News and Opinion on www.breakingbelizenews.com. 31 August 2023.
- ^ a b World Drug Report 2025: Special points of interest (PDF) (PDF). United Nations Office on Drugs and Crime. 2025. Retrieved 29 June 2025.
- ^ a b Zepeda R (16 August 2023). "How the drug wars impact Latin America and the Caribbean development?". King's College London.
- ^ a b "UNODC World Drug Report 2025: Global instability compounding social, economic and security costs of the world drug problem" (PDF). United Nations Office on Drugs and Crime.
- ^ "Cocaine Market Booming as Meth Trafficking Spreads, UN Report Says". Voice of America. 25 June 2023.
- ^ Dillehay TD, Rossen J, Ugent D, Karathanasis A, Vásquez V, Netherly PJ (2010). "Early Holocene coca chewing in northern Peru". Antiquity. 84 (326): 939–953. doi:10.1017/S0003598X00067004. S2CID 162889680.
- ^ a b Lu SL (December 2024). "A Promising Tropical Medicinal Plant: Taiwan as the Production Hub of Japan's Coca Empire". Berichte zur Wissenschaftsgeschichte. 47 (4): 352–381. doi:10.1002/bewi.202400005. PMID 39570053.
- ^ a b Musto DF (January 1998). "International traffic in coca through the early 20th century". Drug and Alcohol Dependence. 49 (2): 145–156. doi:10.1016/s0376-8716(97)00157-9. PMID 9543651.
- ^ Flock E (21 January 2017). "What it was really like to be in Miami during the crazy cocaine boom". pbs.org.
- ^ Housego K (5 April 2004). "As addiction rises, Colombia weighs rolling back decade-old drug legalization". The San Diego Union-Tribune. Associated Press. Retrieved 9 August 2009.
- ^ Murphy J (5 April 2004). "Colombia sinks in sea of legal cocaine, heroin". CBS News. Archived from the original on 5 April 2004. Retrieved 9 August 2009.
- ^ "Heroin and cocaine now legal in Mexico – in small doses | Americas | News | The Independent". The Independent. 23 October 2011. Retrieved 15 May 2016.
- ^ Greenwald G, Reuter P, Lynch T (3 April 2009). "Lessons for Creating Fair and Successful Drug Policies" (PDF). Drug Decriminalization in Portugal. Cato Institute.
- ^ a b Goldstein RA, DesLauriers C, Burda AM (January 2009). "Cocaine: history, social implications, and toxicity--a review". Disease-a-Month. 55 (1): 6–38. doi:10.1016/j.disamonth.2008.10.002. PMID 19081448.
- ^ Valdez LM, Taboada J, Valdez JE (June 2015). "Ancient Use of Coca Leaves in the Peruvian Central Highlands". Journal of Anthropological Research. 71 (2): 231–258. doi:10.3998/jar.0521004.0071.204. hdl:2027/spo.0521004.0071.204. S2CID 163842955.
- ^ Martin RT (October 1970). "The role of coca in the history, religion, and medicine of South American Indians". Economic Botany. 24 (4): 422–438. Bibcode:1970EcBot..24..422M. doi:10.1007/BF02860746. S2CID 34523519.
- ^ Plant T, Aref-Adib G (June 2008). "Travelling to new heights: practical high altitude medicine". British Journal of Hospital Medicine. 69 (6): 348–352. doi:10.12968/hmed.2008.69.6.29626. PMID 18646420.
- ^ Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, et al. (December 2014). "Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update". Wilderness & Environmental Medicine. 25 (4 Suppl): S4–14. doi:10.1016/j.wem.2014.06.017. PMID 25498261.
- ^ World Drug Report 2021: Booklet 4 (PDF). [S.l.]: United Nations Office on Drugs and Crime. 2021. p. 35. ISBN 978-92-1-148361-1. Archived (PDF) from the original on 24 June 2021.
- ^ Room R, Reuter P (January 2012). "How well do international drug conventions protect public health?". Lancet. 379 (9810): 84–91. doi:10.1016/s0140-6736(11)61423-2. PMID 22225673. S2CID 23386203.
The international treaties have also constrained national policy experimentation because they require nation states to criminalise drug use
- ^ "Drug Fact Sheet: Cocaine" (PDF). Drug Enforcement Agency. Archived (PDF) from the original on 21 June 2020. Retrieved 17 June 2022.
- ^ "Drug Fact Sheet: Cocaine" (PDF). US Department for Justice and Drug Enforcement Administration. Archived (PDF) from the original on 21 June 2020. Retrieved 29 June 2024.
- ^ "The tradition of chewing coca". 15 August 2013. Archived from the original on 6 May 2021. Retrieved 6 May 2021.
- ^ Embury-Dennis T. "It's legal to manufacture cocaine and heroin for medical use — and Britain is the world's biggest exporter". Business Insider. Archived from the original on 28 July 2020. Retrieved 17 March 2019.
- ^ "Cocaine: Effects, Hazards & Warnings". Drugs.com. Archived from the original on 28 July 2020. Retrieved 17 March 2019.
- ^ Siegel RK, Elsohly MA, Plowman T, Rury PM, Jones RT (January 1986). "Cocaine in herbal tea". JAMA. 255 (1): 40. doi:10.1001/jama.1986.03370010042021. PMID 3940302.
- ^ Schultes RE (1957). "A New Method of Coca Preparation in the Colombian Amazon". Botanical Museum Leaflets, Harvard University. 17 (9): 241–246. doi:10.5962/p.168505. ISSN 0006-8098. JSTOR 41762172.
- ^ Dwyer C, Sowerby L, Rotenberg BW (August 2016). "Is cocaine a safe topical agent for use during endoscopic sinus surgery?". The Laryngoscope (Review). 126 (8): 1721–1723. doi:10.1002/lary.25836. PMID 27075241.
- ^ Benjamin E, Wong DK, Choa D (December 2004). "'Moffett's' solution: a review of the evidence and scientific basis for the topical preparation of the nose". Clinical Otolaryngology and Allied Sciences. 29 (6): 582–587. doi:10.1111/j.1365-2273.2004.00894.x. PMID 15533141.
- ^ Hamdan AL, Sataloff RT, Hawkshaw MJ (2022). "Topical Anesthesia in Office-Based Laryngeal Surgery". Office-Based Laryngeal Surgery. USA: Springer. pp. 123–137. doi:10.1007/978-3-030-91936-8_6. ISBN 978-3-030-91935-1. Archived from the original on 18 July 2022. Retrieved 18 July 2022.
- ^ "Drug Approval Package: Goprelto (cocaine hydrochloride)". U.S. Food and Drug Administration (FDA). 30 April 2018. Archived from the original on 28 July 2020. Retrieved 30 April 2020.
- ^
This article incorporates text from this source, which is in the public domain: "Numbrino: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 28 July 2020. Retrieved 30 April 2020.
- ^ Berkowitz AL (2022). "Chapter 10: Pupillary Control & Approach to Anisocoria: Cranial Nerves 2 & 3". Clinical Neurology & Neuroanatomy: A Localization-Based Approach (Digital) (2nd ed.). McGraw Hill. ISBN 978-1-260-45336-2.
- ^ Smit D (9 November 2010). "Pharmacologic testing in Horner's syndrome - a new paradigm". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 100 (11): 738–740. doi:10.7196/samj.3773. PMID 21081027.
- ^ Freedman K, Brown S (June 2005). "Topical apraclonidine in the diagnosis of suspected Horner syndrome". Journal of Neuro-Ophthalmology. 25 (2): 83–85. doi:10.1097/01.wno.0000165108.31731.36. PMID 15937427.
- ^ a b World Health Organization (2004). Neuroscience of psychoactive substance use and dependence. World Health Organization. p. 89. ISBN 978-92-4-156235-5. Archived from the original on 30 April 2016.
- ^ World Health Organization (2007). International medical guide for ships. World Health Organization. p. 242. ISBN 978-92-4-154720-8. Archived from the original on 30 April 2016.
- ^ Donroe JH, Tetrault JM (July 2017). "Substance Use, Intoxication, and Withdrawal in the Critical Care Setting". Critical Care Clinics (Review). 33 (3): 543–558. doi:10.1016/j.ccc.2017.03.003. PMID 28601134.
- ^ Lundahl LH, Lukas SE (June 2007). "Negative cocaine effect expectancies are associated with subjective response to cocaine challenge in recreational cocaine users". Addictive Behaviors. 32 (6): 1262–1271. doi:10.1016/j.addbeh.2006.09.001. PMC 4315184. PMID 17110052.
- ^ Fehrman E, Egan V, Gorban AN, Levesley J, Mirkes EM, Muhammad AK (2019). Personality Traits and Drug Consumption. A Story Told by Data. Springer, Cham. arXiv:2001.06520. doi:10.1007/978-3-030-10442-9. ISBN 978-3-030-10441-2. S2CID 151160405.
- ^ Veevers L (1 October 2006). "'Shared banknote' health warning to cocaine users". The Observer. Retrieved 26 July 2008.
- ^ "DrugFacts: Cocaine". National Institute on Drug Abuse. April 2013. Archived from the original on 11 July 2015. Retrieved 11 July 2015.
- ^ "The Dangers Of Snorting Cocaine (Insufflation)". Vertava Health. Archived from the original on 8 April 2022. Retrieved 25 February 2022.
- ^ a b Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, et al. (August 2000). "Effects of route of administration on cocaine-induced dopamine transporter blockade in the human brain". Life Sciences. 67 (12): 1507–1515. doi:10.1016/S0024-3205(00)00731-1. PMID 10983846.
- ^ Mikkelson B (9 July 2002). "Drug Money". Snopes. Retrieved 23 July 2008.
- ^ Abrahamson A (13 November 1994). "Prevalence of Drug-Tainted Money Voids Case Law: Court cites findings that more than 75% of currency in L.A. bears traces of cocaine or other illegal substances". Los Angeles Times. Archived from the original on 4 June 2011. Retrieved 23 July 2008.
- ^ Price DM (6 May 1990). "Use of Drug-Sniffing Dogs Challenged;ACLU Backs Complaint by Men Whose Pocket Cash Was Seized". The Washington Post. Archived from the original on 4 June 2011. Retrieved 23 July 2008.
- ^ Rossen J (19 March 2021). "Sniffing Around the History of the McDonald's 'Cocaine Spoon'". www.mentalfloss.com. Archived from the original on 8 July 2024. Retrieved 14 June 2021.
- ^ "Cocaine terminology". Center for Substance use and Addiction Research – CESAR. University of Maryland. Archived from the original on 9 July 2007.
- ^ Bonkovsky HL, Mehta S (February 2001). "Hepatitis C: a review and update". Journal of the American Academy of Dermatology. 44 (2): 159–182. doi:10.1067/mjd.2001.109311. PMID 11174373.
- ^ "Code of ordinances village of Dundee, Michigan. Chapter 51". Village of Dundee.
- ^ "Code of Ordinances – Clark County, NV". Municode Library. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
- ^ "Township of Middlesex, PA Drugs and Drug Paraphernalia". eCode360. Archived from the original on 13 September 2024. Retrieved 13 September 2024.
- ^ a b Arif A, ed. (1987). Adverse health consequences of cocaine abuse (PDF). Geneva: World Health Organization.
- ^ a b Jeri F (1984). "Coca-paste smoking in some Latin American countries: a severe and unabated form of addiction". Bulletin on Narcotics. 36 (2).
- ^ a b Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany DJ (June 2009). "Cocaine Cardiotoxicity". American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions. 9 (3): 177–196. doi:10.1007/bf03256574. PMID 19463023. S2CID 70385136.
- ^ Mcdonnell PJ (25 May 2007). "Argentina confronts plague named Paco". Los Angeles Times. Retrieved 5 April 2009.
- ^ Legrand C (26 March 2009). "En Argentine, des mères se mobilisent contre le "paco", la drogue des pauvres – Amériques". Le Monde.fr. Retrieved 5 April 2009.
- ^ Valente M (12 September 2006). "DRUGS-ARGENTINA: 'Pasta Base' Destructive but Not Invincible". Ipsnews.net. Archived from the original on 13 February 2009. Retrieved 5 April 2009.
- ^ Ries RK, Miller SC, Fiellin DA (2009). Principles of addiction medicine. Lippincott Williams & Wilkins. p. 137. ISBN 978-0-7817-7477-2. Archived from the original on 4 April 2014. Retrieved 5 January 2014.
- ^ a b Richards JR, Laurin EG (June 2023). "Cocaine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 28613520.
- ^ a b c d "Cocaine as a Teratogen". Embryo Project Encyclopedia. Arizona State University. Retrieved 7 April 2025.
- ^ Singer L, Arendt R, Minnes S (March 1993). "Neurodevelopmental effects of cocaine". Clinics in Perinatology. 20 (1): 245–262. doi:10.1016/S0095-5108(18)30422-6. PMC 4181371. PMID 8458168.
- ^ Flowers D, Clark JF, Westney LS (March 1991). "Cocaine intoxication associated with abruptio placentae". Journal of the National Medical Association. 83 (3): 230–232. PMC 2627035. PMID 2038082.
- ^ Cain MA, Bornick P, Whiteman V (March 2013). "The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy". Clinical Obstetrics and Gynecology. 56 (1): 124–132. doi:10.1097/GRF.0b013e31827ae167. PMID 23314714.
- ^ Singer LT, Minnes S, Short E, Arendt R, Farkas K, Lewis B, et al. (May 2004). "Cognitive outcomes of preschool children with prenatal cocaine exposure". JAMA. 291 (20): 2448–2456. doi:10.1001/jama.291.20.2448. PMC 1901972. PMID 15161895.
- ^ "When breastfeeding or feeding expressed milk is not recommended". Centers for Disease Control and Prevention. 10 August 2021. Retrieved 14 November 2021.
- ^ Eglash A, Leeper K (2020). The Little Green Book of Breastfeeding Management for Physicians & Other Healthcare Providers (7 ed.). Madison, WI: The Institute for the Advancement of Breastfeeding and Lactation Education. ISBN 978-0-9987789-0-7.
- ^ "Street Drugs and pregnancy". March of Dimes. Archived from the original on 5 September 2015. Retrieved 26 May 2009.
- ^ Nutt DJ, King LA, Phillips LD (November 2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet. 376 (9752): 1558–65. CiteSeerX 10.1.1.690.1283. doi:10.1016/S0140-6736(10)61462-6. PMID 21036393. S2CID 5667719.
- ^ Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
- ^ Talarico GP, Crosta ML, Giannico MB, Summaria F, Calò L, Patrizi R (May 2017). "Cocaine and coronary artery diseases: a systematic review of the literature". Journal of Cardiovascular Medicine. 18 (5): 291–294. doi:10.2459/JCM.0000000000000511. PMID 28306693.
- ^ a b c d O'Leary ME, Hancox JC (May 2010). "Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias". British Journal of Clinical Pharmacology. 69 (5): 427–42. doi:10.1111/j.1365-2125.2010.03629.x. PMC 2856043. PMID 20573078.
- ^ "2017 National Drug Threat Assessment" (PDF). Drug Enforcement Administration. 1 October 2017. Retrieved 17 June 2025.
- ^ Solomon N, Hayes J (September 2017). "Levamisole: A High Performance Cutting Agent". Academic Forensic Pathology. 7 (3): 469–476. doi:10.23907/2017.039. PMC 6474566. PMID 31239995.
- ^ "How to Test Your Drugs With Reagents" (PDF). DanceSafe.
- ^ Fredericks C, Yon JR, Alex G, Morton M, Messer T, Bokhari F, et al. (March 2017). "Levamisole-induced Necrosis Syndrome: Presentation and Management". Wounds. 29 (3): 71–76. PMID 28355139.
- ^ Morris GW, Mason BC, Harris Sprunger R, Hake Harris H, White LA, Patterson DA (2012). "Levamisole-adulterated cocaine: a case series". Journal of the American Board of Family Medicine. 25 (4): 531–535. doi:10.3122/jabfm.2012.04.110287. PMID 22773722.
- ^ Lee KC, Ladizinski B, Federman DG (June 2012). "Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge". Mayo Clinic Proceedings. 87 (6): 581–586. doi:10.1016/j.mayocp.2012.03.010. PMC 3498128. PMID 22677078.
- ^ "Cocaine retail markets: multiple indicators suggest continued growth and diversification | www.euda.europa.eu". www.euda.europa.eu.
- ^ Chang A, Osterloh J, Thomas J (September 2010). "Levamisole: a dangerous new cocaine adulterant". Clinical Pharmacology and Therapeutics. 88 (3): 408–411. doi:10.1038/clpt.2010.156. PMID 20668440. S2CID 31414939.
- ^ Tallarida CS, Egan E, Alejo GD, Raffa R, Tallarida RJ, Rawls SM (April 2014). "Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo". Neuropharmacology. 79: 590–595. doi:10.1016/j.neuropharm.2014.01.002. PMC 3989204. PMID 24440755.
- ^ "697. Levamisole". WHO Food Additives Series 27. INCHEM; International Programme on Chemical Safety (IPCS); World Health Organization.
- ^ Iorio L, Davanzo F, Cazzador D, Codirenzi M, Fiorin E, Zanatta E, et al. (August 2024). "Cocaine- and Levamisole-Induced Vasculitis: Defining the Spectrum of Autoimmune Manifestations". Journal of Clinical Medicine. 13 (17): 5116. doi:10.3390/jcm13175116. PMC 11396482. PMID 39274328.
- ^ Cascio MJ, Jen KY (January 2018). "Cocaine/levamisole-associated autoimmune syndrome: a disease of neutrophil-mediated autoimmunity". Current Opinion in Hematology. 25 (1): 29–36. doi:10.1097/MOH.0000000000000393. PMID 29211697. S2CID 23795272.
- ^ Peacock A, Tran LT, Larney S, Stockings E, Santo T, Jones H, et al. (April 2021). "All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis". Addiction. 116 (4): 725–742. doi:10.1111/add.15239. PMC 7914269. PMID 32857457.
- ^ "Cocaine or alcohol, what's worse?". Liberty House Clinic. 17 February 2025. Retrieved 19 April 2025.
- ^ Sharma HS, Muresanu D, Sharma A, Patnaik R (2009). "Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity". International Review of Neurobiology. 88: 297–334. doi:10.1016/S0074-7742(09)88011-2. ISBN 978-0-12-374504-0. PMID 19897082.
- ^ Pereira RB, Andrade PB, Valentão P (October 2015). "A Comprehensive View of the Neurotoxicity Mechanisms of Cocaine and Ethanol". Neurotoxicity Research. 28 (3): 253–267. doi:10.1007/s12640-015-9536-x. PMID 26105693.
- ^ Nicolucci C, Pais ML, Santos AC, Ribeiro FM, Encarnação PM, Silva AL, et al. (2020). "Single Low Dose of Cocaine-Structural Brain Injury Without Metabolic and Behavioral Changes". Frontiers in Neuroscience. 14 589897. doi:10.3389/fnins.2020.589897. PMC 7874143. PMID 33584173.
- ^ Hofmaier T, Luf A, Seddik A, Stockner T, Holy M, Freissmuth M, et al. (July 2014). "Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters". Neurochemistry International. 73 (100): 32–41. doi:10.1016/j.neuint.2013.11.010. PMC 4077236. PMID 24296074.
- ^ Little KY, Ramssen E, Welchko R, Volberg V, Roland CJ, Cassin B (August 2009). "Decreased brain dopamine cell numbers in human cocaine users". Psychiatry Research. 168 (3): 173–80. doi:10.1016/j.psychres.2008.10.034. PMID 19233481. S2CID 27618292.
- ^ Beheshti I (May 2023). "Cocaine Destroys Gray Matter Brain Cells and Accelerates Brain Aging". Biology. 12 (5): 752. doi:10.3390/biology12050752. PMC 10215125. PMID 37237564.
- ^ Lemere F, Smith JW (April 1990). "Hypomanic personality trait in cocaine addiction". British Journal of Addiction. 85 (4): 575–576. doi:10.1111/j.1360-0443.1990.tb01679.x. PMID 2346798.
- ^ Kastner-Bosek A, Dajic I, Mikus N, Weidenauer A, Willeit M (July 2021). "Addicted to Self-esteem: Understanding the neurochemistry of narcissism by using cocaine as a pharmacological model". Journal of Experimental Psychopathology. 12 (3) 20438087211044362. doi:10.1177/20438087211044362.
- ^ Vijayakumar L, Kumar MS, Vijayakumar V (May 2011). "Substance use and suicide". Current Opinion in Psychiatry. 24 (3): 197–202. doi:10.1097/YCO.0b013e3283459242. PMID 21430536. S2CID 206143129.
- ^ Moçambique M, Hoffmann A, Roglio V, Kessler F, Dalbosco C, Schuch J, et al. (24 June 2022). "Prevalence of suicide in cocaine users accessing health services: a systematic review and meta-analysis". Revista Brasileira de Psiquiatria. 44 (4). Sao Paulo, Brazil: 441–448. doi:10.47626/1516-4446-2021-2207. PMC 9375660. PMID 35751594.
- ^ Ayd FJ (2000). Lexicon of psychiatry, neurology, and the neurosciences (2nd ed.). Philadelphia [u.a.]: Lippincott Williams & Wilkins. p. 256. ISBN 978-0-7817-2468-5.
- ^ Hanzlick R, Gowitt GT (February 1991). "Cocaine metabolite detection in homicide victims". JAMA. 265 (6): 760–761. doi:10.1001/jama.1991.03460060092031. PMID 1990194.
- ^ Bland AR, Ersche KD (November 2020). "Deficits in recognizing female facial expressions related to social network in cocaine-addicted men". Drug and Alcohol Dependence. 216 108247. doi:10.1016/j.drugalcdep.2020.108247. PMC 7616971. PMID 32896724.
- ^ Rabin RA, Parvaz MA, Alia-Klein N, Goldstein RZ (April 2022). "Emotion recognition in individuals with cocaine use disorder: the role of abstinence length and the social brain network". Psychopharmacology. 239 (4): 1019–1033. doi:10.1007/s00213-021-05868-x. PMC 8689230. PMID 34089343.
- ^ Conner KR, Pinquart M, Holbrook AP (November 2008). "Meta-analysis of depression and substance use and impairment among cocaine users". Drug and Alcohol Dependence. 98 (1–2): 13–23. doi:10.1016/j.drugalcdep.2008.05.005. PMC 2570759. PMID 18585871.
- ^ Kexel AK, Kluwe-Schiavon B, Baumgartner MR, Engeli EJ, Visentini M, Kirschbaum C, et al. (October 2022). "Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users". Translational Psychiatry. 12 (1) 443. doi:10.1038/s41398-022-02204-5. PMC 9554190. PMID 36220809.
- ^ Brady KT, Lydiard RB, Malcolm R, Ballenger JC (December 1991). "Cocaine-induced psychosis". The Journal of Clinical Psychiatry. 52 (12): 509–512. PMID 1752853.
- ^ a b c Thirthalli J, Benegal V (May 2006). "Psychosis among substance users". Current Opinion in Psychiatry. 19 (3): 239–245. doi:10.1097/01.yco.0000218593.08313.fd. PMID 16612208. S2CID 13350537.
- ^ Elliott A, Mahmood T, Smalligan RD (2012). "Cocaine bugs: a case report of cocaine-induced delusions of parasitosis". The American Journal on Addictions. 21 (2): 180–181. doi:10.1111/j.1521-0391.2011.00208.x. PMID 22332864.
- ^ DiSclafani II A, Hall RC, Gardner ER (October 1981). "Drug-induced psychosis: emergency diagnosis and management". Psychosomatics. 22 (10): 845–50, 855. doi:10.1016/s0033-3182(81)73092-5. PMID 7313045.
- ^ Heesch CM, Negus BH, Keffer JH, Snyder RW, Risser RC, Eichhorn EJ (August 1995). "Effects of cocaine on cortisol secretion in humans". The American Journal of the Medical Sciences. 310 (2): 61–4. doi:10.1097/00000441-199508000-00004. PMID 7631644. S2CID 11042810.
- ^ a b Ambre JJ, Belknap SM, Nelson J, Ruo TI, Shin SG, Atkinson AJ (July 1988). "Acute tolerance to cocaine in humans". Clinical Pharmacology and Therapeutics. 44 (1): 1–8. doi:10.1038/clpt.1988.104. PMID 3390996. S2CID 44253676.
- ^ Pudiak CM, KuoLee R, Bozarth MA (July 2014). "Tolerance to cocaine in brain stimulation reward following continuous cocaine infusions". Pharmacology, Biochemistry, and Behavior. 122: 246–52. doi:10.1016/j.pbb.2014.04.006. PMID 24768900. S2CID 207332822.
- ^ Gullapalli BT, Natarajan A, Angarita GA, Malison RT, Ganesan D, Rahman T (21 June 2019). "On-body Sensing of Cocaine Craving, Euphoria and Drug-Seeking Behavior Using Cardiac and Respiratory Signals". Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies. 3 (2): 1–31. doi:10.1145/3328917. S2CID 195357215.
- ^ Calipari ES, Ferris MJ, Jones SR (January 2014). "Extended access of cocaine self-administration results in tolerance to the dopamine-elevating and locomotor-stimulating effects of cocaine". Journal of Neurochemistry. 128 (2): 224–32. doi:10.1111/jnc.12452. PMC 3947316. PMID 24102293.
- ^ a b Zhao W (2008). Mechanisms Mediating Sex Differences in the Effects of Cocaine. University of Michigan. p. 3. ISBN 978-0-549-99458-9. Archived from the original on 4 April 2014. Retrieved 25 September 2012.
- ^ Boles SM, Miotto K (March–April 2003). "Substance abuse and violence: A review of the literature". Aggression and Violent Behavior. 8 (2): 155–174. doi:10.1016/S1359-1789(01)00057-X.
- ^ Pergolizzi JV, Magnusson P, LeQuang JA, Breve F, Varrassi G (April 2021). "Cocaine and Cardiotoxicity: A Literature Review". Cureus. 13 (4) e14594. doi:10.7759/cureus.14594. ISSN 2168-8184. PMC 8136464. PMID 34036012.
- ^ a b Treadwell SD, Robinson TG (June 2007). "Cocaine use and stroke". Postgraduate Medical Journal. 83 (980): 389–394. doi:10.1136/pgmj.2006.055970. PMC 2600058. PMID 17551070.
- ^ Havakuk O, Rezkalla SH, Kloner RA (July 2017). "The Cardiovascular Effects of Cocaine". Journal of the American College of Cardiology (Review). 70 (1): 101–113. doi:10.1016/j.jacc.2017.05.014. PMID 28662796.
- ^ Vonmoos M, Hulka LM, Preller KH, Minder F, Baumgartner MR, Quednow BB (August 2014). "Cognitive impairment in cocaine users is drug-induced but partially reversible: evidence from a longitudinal study". Neuropsychopharmacology. 39 (9): 2200–2210. doi:10.1038/npp.2014.71. PMC 4104339. PMID 24651468.
- ^ Frazer KM, Richards Q, Keith DR (August 2018). "The long-term effects of cocaine use on cognitive functioning: A systematic critical review". Behavioural Brain Research. 348: 241–262. doi:10.1016/j.bbr.2018.04.005. PMID 29673580.
- ^ Sharma HS, Muresanu D, Sharma A, Patnaik R (2009). "Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity". International Review of Neurobiology. 88: 297–334. doi:10.1016/S0074-7742(09)88011-2. ISBN 978-0-12-374504-0. PMID 19897082.
- ^ Karch SB (2009). Karch's pathology of drug abuse (4th ed.). Boca Raton: CRC Press. p. 70. ISBN 978-0-8493-7881-2. Archived from the original on 10 September 2017.
- ^ Shekarchizadeh H, Khami MR, Mohebbi SZ, Ekhtiari H, Virtanen JI (September 2013). "Oral Health of Drug Abusers: A Review of Health Effects and Care". Iranian Journal of Public Health. 42 (9): 929–940. PMC 4453891. PMID 26060654.
- ^ Baigent M (2003). "Physical complications of substance abuse: what the psychiatrist needs to know". Curr Opin Psychiatry. 16 (3): 291–296. doi:10.1097/00001504-200305000-00004.
- ^ "Cocaine". National Institute on Drug Abuse (NIDA). U.S. Department of Health and Human Services. Archived from the original on 6 June 2022.
- ^ Paludetto LS, Florence LL, Torales J, Ventriglio A, Castaldelli-Maia JM (March 2024). "Mapping the Neural Substrates of Cocaine Craving: A Systematic Review". Brain Sciences. 14 (4): 329. doi:10.3390/brainsci14040329. PMC 11048489. PMID 38671981.
- ^ Hormes JM, Coffey SF, Drobes DJ, Saladin ME (January 2012). "The Obsessive Compulsive Cocaine Use Scale: development and initial validation of a self-rated instrument for the quantification of thoughts about cocaine use". Drug and Alcohol Dependence. 120 (1–3): 250–254. doi:10.1016/j.drugalcdep.2011.07.024. PMC 3245789. PMID 21890282.
- ^ Kirschner M, Sladky R, Haugg A, Stämpfli P, Jehli E, Hodel M, et al. (November 2018). "Self-regulation of the dopaminergic reward circuit in cocaine users with mental imagery and neurofeedback". eBioMedicine. 37: 489–498. doi:10.1016/j.ebiom.2018.10.052. PMC 6286189. PMID 30377073.
- ^ Walsh SL, Stoops WW, Moody DE, Lin SN, Bigelow GE (August 2009). "Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics". Experimental and Clinical Psychopharmacology. 17 (4): 205–216. doi:10.1037/a0016469. PMC 2811070. PMID 19653786.
- ^ Gold M (16 October 2022). "Fentanyl-Adulterated Cocaine: Strategies To Address The New Normal". Addiction Policy Forum. Archived from the original on 17 December 2022. Retrieved 17 December 2022.
- ^ Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. (GBD 2017 Causes of Death Collaborators) (November 2018). "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017". Lancet. 392 (10159): 1736–1788. doi:10.1016/S0140-6736(18)32203-7. PMC 6227606. PMID 30496103.
- ^ Hampton WH, Hanik I, Olson IR (2019). "[Substance Abuse and White Matter: Findings, Limitations, and Future of Diffusion Tensor Imaging Research]". Drug and Alcohol Dependence. 197 (4): 288–298. doi:10.1016/j.drugalcdep.2019.02.005. PMC 6440853. PMID 30875650.
- ^ Fernàndez-Castillo N, Cabana-Domínguez J, Corominas R, Cormand B (January 2022). "Molecular genetics of cocaine use disorders in humans". Molecular Psychiatry. 27 (1): 624–639. doi:10.1038/s41380-021-01256-1. PMC 8960411. PMID 34453125.
- ^ Hope BT (May 1998). "Cocaine and the AP-1 transcription factor complex". Annals of the New York Academy of Sciences. 844 (1): 1–6. Bibcode:1998NYASA.844....1H. doi:10.1111/j.1749-6632.1998.tb08216.x. PMID 9668659. S2CID 11683570. Archived from the original on 28 July 2020. Retrieved 30 June 2019.
- ^ a b Kelz MB, Chen J, Carlezon WA, Whisler K, Gilden L, Beckmann AM, et al. (September 1999). "Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine". Nature. 401 (6750): 272–6. Bibcode:1999Natur.401..272K. doi:10.1038/45790. PMID 10499584. S2CID 4390717.
- ^ Colby CR, Whisler K, Steffen C, Nestler EJ, Self DW (March 2003). "Striatal cell type-specific overexpression of DeltaFosB enhances incentive for cocaine". The Journal of Neuroscience. 23 (6): 2488–93. doi:10.1523/JNEUROSCI.23-06-02488.2003. PMC 6742034. PMID 12657709.
- ^ a b Nestler EJ, Barrot M, Self DW (September 2001). "DeltaFosB: a sustained molecular switch for addiction". Proceedings of the National Academy of Sciences of the United States of America. 98 (20): 11042–6. Bibcode:2001PNAS...9811042N. doi:10.1073/pnas.191352698. PMC 58680. PMID 11572966.
- ^ de Souza MF, Gonçales TA, Steinmetz A, Moura DJ, Saffi J, Gomez R, et al. (April 2014). "Cocaine induces DNA damage in distinct brain areas of female rats under different hormonal conditions". Clinical and Experimental Pharmacology & Physiology. 41 (4): 265–9. doi:10.1111/1440-1681.12218. PMID 24552452. S2CID 20849951.
- ^ Alvarenga TA, Andersen ML, Ribeiro DA, Araujo P, Hirotsu C, Costa JL, et al. (January 2010). "Single exposure to cocaine or ecstasy induces DNA damage in brain and other organs of mice". Addiction Biology. 15 (1): 96–9. doi:10.1111/j.1369-1600.2009.00179.x. PMID 19878142. S2CID 21347765.
- ^ Dabin J, Fortuny A, Polo SE (June 2016). "Epigenome Maintenance in Response to DNA Damage". Molecular Cell. 62 (5): 712–27. doi:10.1016/j.molcel.2016.04.006. PMC 5476208. PMID 27259203.
- ^ Oliva F, Mangiapane C, Nibbio G, Berchialla P, Colombi N, Vigna-Taglianti FD (November 2021). "Prevalence of cocaine use and cocaine use disorder among adult patients with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". Journal of Psychiatric Research. 143: 587–598. doi:10.1016/j.jpsychires.2020.11.021. hdl:2318/1768539. PMID 33199055.
- ^ Roncero C, Daigre C, Barral C, Ros-Cucurull E, Grau-López L, Rodríguez-Cintas L, et al. (2014). "Neuroticism associated with cocaine-induced psychosis in cocaine-dependent patients: a cross-sectional observational study". PLOS ONE. 9 (9) e106111. Bibcode:2014PLoSO...9j6111R. doi:10.1371/journal.pone.0106111. PMC 4177812. PMID 25254365.
- ^ Cocaine Anonymous (13 November 2007). "And All Other Mind-Altering Substances". Archived from the original on 4 March 2009. Retrieved 15 November 2007.
- ^ McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC 4009342. PMID 24442756.
- ^ Jalali A (October 2023). "Cocaine Nose Correction: A Nonsurgical Approach Using a Novel Hyaluronic Acid Filler". Plastic and Reconstructive Surgery. Global Open. 11 (10) e5329. doi:10.1097/GOX.0000000000005329. PMC 10561808. PMID 37817926.
- ^ Taams KO, Taams SJ (January 2022). "The Bilateral Trans Alar Forehead Flap to Reconstruct the Cocaine Nose: A Case Report". Plastic and Reconstructive Surgery. Global Open. 10 (1) e4044. doi:10.1097/GOX.0000000000004044. PMC 8785930. PMID 35083102.
- ^ Chatzaraki V, Schweitzer W, Thali MJ, Ampanozi G (September 2019). "Nasal Septum Defects Detected on Postmortem Computed Tomography" (PDF). The American Journal of Forensic Medicine and Pathology. 40 (3): 279–284. doi:10.1097/PAF.0000000000000482. PMID 30985333.
- ^ Schwartz R, Estroff T, Fairbanks D, Hoffmann N (January 1989). "Nasal symptoms associated with cocaine abuse during adolescence". Archives of Otolaryngology–Head & Neck Surgery. 115 (1): 63–64. doi:10.1001/archotol.1989.01860250065028. PMID 2909232.
- ^ a b "Fraser 'Nose' The Irreparable Damage Cocaine Use Can Do". National Health Service (NHS) Lanarkshire.
- ^ a b "Patients face losing noses due to cocaine use, medics warn". BBC. 9 March 2023.
- ^ Maloney B, Hinchion K, Conlon N, Omer O, Pierse D (September 2024). "Cocaine-induced destruction of the palate: a diagnostic and management challenge". British Dental Journal. 237 (6): 465–471. doi:10.1038/s41415-024-7834-5. PMC 11436349. PMID 39333814.
- ^ Trimarchi M, Bondi S, Della Torre E, Terreni MR, Bussi M (August 2017). "Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis". Acta Otorhinolaryngologica Italica. 37 (4): 281–285. doi:10.14639/0392-100X-1586. PMC 5584099. PMID 28663599.
- ^ Schreiber BE, Twigg S, Marais J, Keat AC (April–May 2014). "Saddle-nose deformities in the rheumatology clinic". Ear, Nose, & Throat Journal (Review). 93 (4–5): E45 – E47. PMID 24817241.
- ^ a b Pagliaro L, Pagliaro AM (2004). Pagliaros' Comprehensive Guide to Drugs and Substances of Abuse. Washington, D.C.: American Pharmacists Association. ISBN 978-1-58212-066-9.
- ^ Hansen FV, Kiehn OT, Lomholt AF, Ringdom H, Aanæs K (October 2023). "[Not Available]". Ugeskrift for Laeger. 185 (40). PMID 37874002.
- ^ Millard DR, Mejia FA (February 2001). "Reconstruction of the nose damaged by cocaine". Plastic and Reconstructive Surgery. 107 (2): 419–424. doi:10.1097/00006534-200102000-00018. PMID 11214057.
- ^ Min R (28 March 2024). "Doctors in Belgium see serious nose lesions amid rising cocaine use". euronews.
- ^ "Overdose Death Rates". National Institute on Drug Abuse (NIDA). 21 August 2024.
- ^ O'Leary ME, Hancox JC (May 2010). "Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias". British Journal of Clinical Pharmacology. 69 (5): 427–442. doi:10.1111/j.1365-2125.2010.03629.x. PMC 2856043. PMID 20573078.
- ^ "Cocaine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2017. PMID 31643773.
- ^ Lawrie E (23 October 2024). "Cocaine use fuels record high in drug deaths". www.bbc.com.
- ^ Laizure SC, Mandrell T, Gades NM, Parker RB (January 2003). "Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases". Drug Metabolism and Disposition. 31 (1): 16–20. doi:10.1124/dmd.31.1.16. PMID 12485948.
- ^ Pergolizzi J, Breve F, Magnusson P, LeQuang JA, Varrassi G (February 2022). "Cocaethylene: When Cocaine and Alcohol Are Taken Together". Cureus. 14 (2) e22498. doi:10.7759/cureus.22498. PMC 8956485. PMID 35345678.
- ^ van Amsterdam J, Gresnigt F, van den Brink W (March 2024). "Cardiovascular Risks of Simultaneous Use of Alcohol and Cocaine-A Systematic Review". Journal of Clinical Medicine. 13 (5): 1475. doi:10.3390/jcm13051475. PMC 10935323. PMID 38592322.
- ^ Liu X, Singer ME (June 2023). "Intentional use of both opioids and cocaine in the United States". Preventive Medicine Reports. 33 102227. doi:10.1016/j.pmedr.2023.102227. PMC 10201855. PMID 37223567.
- ^ Barnett G, Hawks R, Resnick R (1981). "Cocaine pharmacokinetics in humans". Journal of Ethnopharmacology. 3 (2–3): 353–66. doi:10.1016/0378-8741(81)90063-5. PMID 7242115.; Jones, supra note 19; Wilkinson et al., Van Dyke et al.
- ^ Sachkova A, Doetsch DA, Jensen O, Brockmöller J, Ansari S (October 2021). "How do psychostimulants enter the human brain? Analysis of the role of the proton-organic cation antiporter". Biochemical Pharmacology. 192 114751. doi:10.1016/j.bcp.2021.114751. PMID 34464621.
- ^ Tega Y, Tabata H, Kurosawa T, Kitamura A, Itagaki F, Oshitari T, et al. (January 2021). "Structural Requirements for Uptake of Diphenhydramine Analogs into hCMEC/D3 Cells Via the Proton-Coupled Organic Cation Antiporter". Journal of Pharmaceutical Sciences. 110 (1): 397–403. Bibcode:2021JPhmS.110..397T. doi:10.1016/j.xphs.2020.09.001. PMID 32898521.
- ^ Chapy H, Smirnova M, André P, Schlatter J, Chiadmi F, Couraud PO, et al. (October 2014). "Carrier-mediated cocaine transport at the blood–brain barrier as a putative mechanism in addiction liability". The International Journal of Neuropsychopharmacology. 18 (1) pyu001. doi:10.1093/ijnp/pyu001. PMC 4368859. PMID 25539501.
- ^ Sachkova A, Jensen O, Dücker C, Ansari S, Brockmöller J (September 2022). "The mystery of the human proton-organic cation antiporter: One transport protein or many?". Pharmacology & Therapeutics. 239 108283. doi:10.1016/j.pharmthera.2022.108283. PMID 36162727. S2CID 252527522.
- ^ Ambre J, Ruo TI, Nelson J, Belknap S (November 1988). "Urinary excretion of cocaine, benzoylecgonine, and ecgonine methyl ester in humans". Journal of Analytical Toxicology. 12 (6): 301–6. doi:10.1093/jat/12.6.301. PMID 3244269.
- ^ Kolbrich EA, Barnes AJ, Gorelick DA, Boyd SJ, Cone EJ, Huestis MA (October 2006). "Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration". Journal of Analytical Toxicology. 30 (8): 501–10. doi:10.1093/jat/30.8.501. PMID 17132243. Archived from the original on 18 July 2012.
- ^ "Schaffer Library of Drug Policy: Urine Testing for Cocaine". Retrieved 3 April 2025.
- ^ Baselt R (2011). Disposition of Toxic Drugs and Chemicals in Man (9th ed.). Seal Beach, California: Biomedical Publications. pp. 390–394.
- ^ Czykanski M (30 December 2015). "Cocaine Metabolites in Hair". Chemistry Views. Archived from the original on 22 July 2019. Retrieved 22 July 2019.
- ^ Proebstl L, Kamp F, Manz K, Krause D, Adorjan K, Pogarell O, et al. (June 2019). "Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies". European Psychiatry. 59: 15–24. doi:10.1016/j.eurpsy.2019.03.003. PMID 30981746.
- ^ "How does cocaine produce its effects?". Archived from the original on 18 January 2022. Retrieved 12 May 2021.
- ^ Wise RA, Robble MA (January 2020). "Dopamine and Addiction". Annual Review of Psychology. 71 (1): 79–106. doi:10.1146/annurev-psych-010418-103337. PMID 31905114.
- ^ Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. S2CID 15573624. (Table V. on page 37)
- ^ Hummel M, Unterwald EM (April 2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". Journal of Cellular Physiology. 191 (1): 17–27. doi:10.1002/jcp.10078. PMID 11920678. S2CID 40444893.
- ^ Carta M, Allan AM, Partridge LD, Valenzuela CF (January 2003). "Cocaine inhibits 5-HT3 receptor function in neurons from transgenic mice overexpressing the receptor". European Journal of Pharmacology. 459 (2–3): 167–9. doi:10.1016/S0014-2999(02)02867-4. PMID 12524142.
- ^ Filip M, Bubar MJ, Cunningham KA (September 2004). "Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 1246–54. doi:10.1124/jpet.104.068841. PMID 15131246. S2CID 25809734.
- ^ Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. (July 2008). "The binding sites for cocaine and dopamine in the dopamine transporter overlap". Nature Neuroscience. 11 (7): 780–9. doi:10.1038/nn.2146. PMC 2692229. PMID 18568020.
- ^ Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. (April 1997). "Relationship between subjective effects of cocaine and dopamine transporter occupancy". Nature. 386 (6627): 827–830. Bibcode:1997Natur.386..827V. doi:10.1038/386827a0. PMID 9126740.
- ^ a b Heal DJ, Gosden J, Smith SL (December 2014). "Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine". Neuropharmacology. CNS Stimulants. 87: 19–40. doi:10.1016/j.neuropharm.2014.06.012. PMID 24953830.
- ^ Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, et al. (September 1996). "Relationship between psychostimulant-induced "high" and dopamine transporter occupancy". Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10388–10392. doi:10.1073/pnas.93.19.10388. PMC 38394. PMID 8816810.
- ^ Schmitt KC, Reith ME (2011). "The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors". PLOS ONE. 6 (10) e25790. Bibcode:2011PLoSO...625790S. doi:10.1371/journal.pone.0025790. PMC 3197159. PMID 22043293.
- ^ Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, et al. (April 2003). "IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity". Journal of Immunology. 170 (7). Baltimore, Md.: 3585–91. doi:10.4049/jimmunol.170.7.3585. PMID 12646621. Lay summary in: "Sigma Receptors Play Role in Cocaine-induced Suppression of Immune System". ScienceDaily. 6 May 2003.
- ^ Lluch J, Rodríguez-Arias M, Aguilar MA, Miñarro J (November 2005). "Role of dopamine and glutamate receptors in cocaine-induced social effects in isolated and grouped male OF1 mice". Pharmacology Biochemistry and Behavior. 82 (3): 478–87. doi:10.1016/j.pbb.2005.10.003. PMID 16313950. S2CID 13307446.
- ^ Knuepfer MM (March 2003). "Cardiovascular disorders associated with cocaine use: myths and truths". Pharmacology & Therapeutics. 97 (3): 181–222. doi:10.1016/S0163-7258(02)00329-7. PMID 12576134.
- ^ "Drugbank website "drug card", "(DB00907)" for Cocaine: Giving ten targets of the molecule in vivo, including dopamine/serotonin sodium channel affinity & K-opioid affinity". Drugbank.ca. Archived from the original on 20 February 2010. Retrieved 9 March 2010.
- ^ Uz T, Akhisaroglu M, Ahmed R, Manev H (December 2003). "The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice". Neuropsychopharmacology. 28 (12): 2117–23. doi:10.1038/sj.npp.1300254. PMID 12865893.
- ^ McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, et al. (June 2005). "Regulation of dopaminergic transmission and cocaine reward by the Clock gene". Proceedings of the National Academy of Sciences of the United States of America. 102 (26): 9377–81. Bibcode:2005PNAS..102.9377M. doi:10.1073/pnas.0503584102. PMC 1166621. PMID 15967985.
- ^ Aguinaga D, Medrano M, Cordomí A, Jiménez-Rosés M, Angelats E, Casanovas M, et al. (February 2019). "Cocaine Blocks Effects of Hunger Hormone, Ghrelin, Via Interaction with Neuronal Sigma-1 Receptors". Molecular Neurobiology. 56 (2): 1196–1210. doi:10.1007/s12035-018-1140-7. hdl:2445/127306. PMID 29876881. S2CID 46964405.
- ^ Bouhlal S, Ellefsen KN, Sheskier MB, Singley E, Pirard S, Gorelick DA, et al. (November 2017). "Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses". Drug and Alcohol Dependence. 180: 68–75. doi:10.1016/j.drugalcdep.2017.07.033. PMC 5654385. PMID 28881319.
- ^ Carey RJ, Damianopoulos EN, Shanahan AB (January 2008). "Cocaine effects on behavioral responding to a novel object placed in a familiar environment". Pharmacology Biochemistry and Behavior. 88 (3): 265–71. doi:10.1016/j.pbb.2007.08.010. PMID 17897705. S2CID 22711773.
- ^ Cotton S (February 2016). "Cocaine: The notorious recreational drug". Molecule of the Month. University of Bristol. Archived from the original on 8 July 2024. Retrieved 4 May 2020.
- ^ Humphrey AJ, O'Hagan D (October 2001). "Tropane alkaloid biosynthesis. A century-old problem unresolved". Natural Product Reports. 18 (5): 494–502. doi:10.1039/b001713m. PMID 11699882.
- ^ Amara SB, Koslowski T, Zaidi A (2021). "Quantum Chemistry of Cocaine and its Isomers I: Energetics, Reactivity and Solvation". South African Journal of Chemistry. 75. doi:10.17159/0379-4350/2021/v75a3.
- ^ Drake LR, Scott PJ (October 2018). "DARK Classics in Chemical Neuroscience: Cocaine". ACS Chemical Neuroscience. 9 (10): 2358–2372. doi:10.1021/acschemneuro.8b00117. PMC 6197930. PMID 29630337.
- ^ a b Kohnen-Johannsen KL, Kayser O (February 2019). "Tropane Alkaloids: Chemistry, Pharmacology, Biosynthesis and Production". Molecules. 24 (4): 796. doi:10.3390/molecules24040796. PMC 6412926. PMID 30813289.
- ^ Leete E (August 1990). "Recent Developments in the Biosynthesis of the Tropane Alkaloids1". Planta Medica. 56 (4): 339–352. Bibcode:1990PlMed..56..339L. doi:10.1055/s-2006-960979. PMID 2236285.
- ^ Wilkins A (25 November 2022). "Genetically modified tobacco plant produces cocaine in its leaves". New Scientist. Archived from the original on 27 November 2022. Retrieved 27 November 2022.
- ^ Crawford D (22 July 2009). "Drug torches 'don't always work'". BBC News.
- ^ Taylor J (14 June 2013). "Drug torches for bouncers 'don't always spot cocaine'". BBC News.
- ^ Gabrielson R (22 June 2016). "Meet the Chemist Behind Many Popular—and Faulty—Police Drug Kits". Pacific Standard. Archived from the original on 8 August 2020. Retrieved 21 April 2020.
- ^ Gabrielson R, Sanders T (7 July 2016). "How a $2 Roadside Drug Test Sends Innocent People to Jail". The New York Times. Archived from the original on 1 January 2022. Retrieved 21 April 2020.
- ^ Travnikoff B (1 April 1983). "Semiquantitative screening test for cocaine". Analytical Chemistry. 55 (4): 795–796. Bibcode:1983AnaCh..55..795T. doi:10.1021/ac00255a048. ISSN 0003-2700.
- ^ Busnel R, Manrique López H (July 2023). "The political economy of a failed drug reform: Insights from Peru's main legal coca valley". The International Journal on Drug Policy. 117 104050. doi:10.1016/j.drugpo.2023.104050. PMID 37267739.
- ^ Grisaffi T, Ledebur K (31 March 2016). "Citizenship or Repression? Coca, Eradication and Development in the Andes". Stability: International Journal of Security and Development. 5 (1) 3. doi:10.5334/sta.440. ISSN 2165-2627.
- ^ "World Anti-Doping Code: International Standard Prohibited List 2017" (PDF). January 2017.
- ^ "Cocaine". DEA.
- ^ Franklin J (18 August 2009). "The world's first cocaine bar". The Guardian. ISSN 0261-3077. Archived from the original on 12 January 2017. Retrieved 23 December 2016.
- ^ Grisaffi T. "The Cato Accord: Bolivia's Humane and Effective Approach to Controlling Coca Cultivation" (PDF). ain-bolivia.org. Archived (PDF) from the original on 3 May 2016. Retrieved 12 January 2017.
- ^ "Therapeutic Goods (Poisons Standard—October 2023) Instrument 2023". Federal Register of Legislation. Australian Government. 26 September 2023. Retrieved 22 January 2024.
- ^ "Illicit drug use". Australian Institute of Health and Welfare. 13 December 2023. Archived from the original on 20 January 2024. Retrieved 22 January 2024.
- ^ "Misuse of Drugs Act 1981" (PDF). Western Australian Legislation. Government of Western Australia Department of Justice Parliamentary Counsel's Office. Archived (PDF) from the original on 17 February 2024. Retrieved 22 January 2024.
- ^ a b c d Gootenberg P, ed. (1999). Cocaine: Global Histories. London: Routledge. ISBN 978-0-203-02646-5.
- ^ Madge T (2001). White Mischief: A Cultural History of Cocaine. Edinburgh: Mainstream Publishing Company. p. 106. ISBN 978-1-84018-405-1.
- ^ "Narcotic drug addiction". American Medicine. American-Medicine Publishing Company: 799. November 1915. Archived from the original on 9 May 2018. Retrieved 29 April 2018.
- ^ Brown E, Barganier G (2018). Race and Crime: Geographies of Injustice. Oakland, California: University of California Press. pp. 207–209. ISBN 978-0-520-29418-9. Archived from the original on 12 April 2023. Retrieved 21 November 2021.
- ^ Moore NM (2015). The Political Roots of Racial Tracking in American Criminal Justice. New York, NY: Cambridge University Press. p. 270. ISBN 978-1-107-02297-3. Archived from the original on 6 April 2023. Retrieved 21 November 2021.
- ^ Glaser J (2015). Suspect Race: Causes and Consequences of Racial Profiling. New York, NY: Oxford University Press. p. 7. ISBN 978-0-19-537040-9. Archived from the original on 12 April 2023. Retrieved 21 November 2021.
- ^ "Field Listing – Illicit drugs (by country)". Cia.gov. Archived from the original on 29 December 2010. Retrieved 15 January 2011.
- ^ "Cocaine – the current situation in Europe (European Drug Report 2024) | www.euda.europa.eu". www.euda.europa.eu.
- ^ a b c d UNODC (2006). Part 2. Environmental Effects of Illicit Drug Cultivation and Processing (PDF) (Report). Retrieved 6 May 2019.
- ^ McSweeney K (2015). "The Impact of Drug Policy on the Environment" (PDF). Retrieved 7 May 2019.
- ^ a b c Burns-Edel T (2016). "Environmental Impacts of Illicit Drug Production. Issue" (PDF). Global Societies Journal. 4.
- ^ Hulme S, Hughes CE, Nielsen S (February 2020). "The price and mark up of pharmaceutical drugs supplied on the black market". The International Journal on Drug Policy. 76 102626. doi:10.1016/j.drugpo.2019.102626. PMID 31841773.
- ^ "Organized Crime Module 16 Key Issues: Terrorism and drug trafficking". www.unodc.org.
- ^ Transnational Organized Crime in West Africa: A Threat Assessment (PDF) (Report). United Nations Office on Drugs and Crime (UNODC). 2013.
- ^ "Linkages Between Organized Crime and Terrorism" (PDF). United Nations Office on Drugs and Crime (UNODC). 2019.
- ^ van Royen M (28 December 2000). "Driven Mad by Itch". NRC Handelsblad.
- ^ a b O'Shaughnessy H, Branford S (2005). Chemical Warfare in Colombia: The Costs of Coca Fumigation. London: Latin America Bureau. ISBN 978-1-899365-68-5.
- ^ "Colombia to ban coca spraying herbicide glyphosate". BBC. 10 May 2015.
- ^ McSweeney K (June 2020). "Reliable drug war data: The Consolidated Counterdrug Database and cocaine interdiction in the "Transit Zone"". The International Journal on Drug Policy. 80 102719. doi:10.1016/j.drugpo.2020.102719. PMID 32416537.
- ^ Janda KD, Treweek JB (December 2011). "Vaccines targeting drugs of abuse: is the glass half-empty or half-full?". Nature Reviews. Immunology. 12 (1): 67–72. doi:10.1038/nri3130. PMID 22173478.
- ^ Anthenelli RM, Somoza E (September 2010). "Vaccine for cocaine addiction: A promising new immunotherapy" (PDF). Current Psychiatry. 9 (9): 16–20.
- ^ Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, et al. (June 2017). "Development of a Clinically Viable Heroin Vaccine". Journal of the American Chemical Society. 139 (25): 8601–8611. Bibcode:2017JAChS.139.8601B. doi:10.1021/jacs.7b03334. PMC 5612493. PMID 28574716.
- ^ Narasimhan D, Woods JH, Sunahara RK (February 2012). "Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction". Future Medicinal Chemistry. 4 (2): 137–50. doi:10.4155/fmc.11.194. PMC 3290992. PMID 22300094.
- ^ Teobaldo L (1994). "The Standard Low Dose of Oral Cocaine: Used for Treatment of Cocaine Dependence" (PDF). Substance Abuse. 15 (4): 215–220. Archived (PDF) from the original on 2 June 2014.
- ^ Mariani JJ, Khantzian EJ, Levin FR (March 2014). "The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update". The American Journal on Addictions. 23 (2): 189–193. doi:10.1111/j.1521-0391.2013.12086.x. PMC 4227391. PMID 25187055.
- ^ Kandel ER, Kandel DB (September 2014). "Shattuck Lecture. A molecular basis for nicotine as a gateway drug". The New England Journal of Medicine. 371 (10): 932–943. doi:10.1056/NEJMsa1405092. PMC 4353486. PMID 25184865.
- ^ Keyes KM, Hamilton A, Kandel DB (June 2016). "Birth Cohorts Analysis of Adolescent Cigarette Smoking and Subsequent Marijuana and Cocaine Use". American Journal of Public Health. 106 (6): 1143–1149. doi:10.2105/AJPH.2016.303128. PMC 4880234. PMID 27077359.
- ^ Ren M, Lotfipour S (August 2019). "Nicotine Gateway Effects on Adolescent Substance Use". The Western Journal of Emergency Medicine. 20 (5): 696–709. doi:10.5811/westjem.2019.7.41661. PMC 6754186. PMID 31539325.
- ^ Griffin EA, Melas PA, Zhou R, Li Y, Mercado P, Kempadoo KA, et al. (November 2017). "Prior alcohol use enhances vulnerability to compulsive cocaine self-administration by promoting degradation of HDAC4 and HDAC5". Science Advances. 3 (11) e1701682. Bibcode:2017SciA....3E1682G. doi:10.1126/sciadv.1701682. PMC 5665598. PMID 29109977.
- ^ Anderson EM, Penrod RD, Barry SM, Hughes BW, Taniguchi M, Cowan CW (August 2019). "It is a complex issue: emerging connections between epigenetic regulators in drug addiction". The European Journal of Neuroscience. 50 (3): 2477–2491. doi:10.1111/ejn.14170. PMID 30251397. S2CID 52816486.
- ^ Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, et al. (May 2011). "Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)". Drug and Alcohol Dependence. 115 (1–2): 120–130. doi:10.1016/j.drugalcdep.2010.11.004. PMC 3069146. PMID 21145178.
- ^ Bickel WK, Snider SE, Quisenberry AJ, Stein JS, Hanlon CA (2016). "Competing neurobehavioral decision systems theory of cocaine addiction". Competing neurobehavioral decision systems theory of cocaine addiction: From mechanisms to therapeutic opportunities. Progress in Brain Research. Vol. 223. pp. 269–293. doi:10.1016/bs.pbr.2015.07.009. ISBN 978-0-444-63545-7. PMC 5495192. PMID 26806781.
- ^ Dimitrijevic N, Dzitoyeva S, Manev H (August 2004). "An automated assay of the behavioral effects of cocaine injections in adult Drosophila". Journal of Neuroscience Methods. 137 (2): 181–184. doi:10.1016/j.jneumeth.2004.02.023. PMID 15262059. S2CID 19882594.
- ^ Corrêa F (30 May 2023). "Brasileiros desenvolvem vacina contra crack e cocaína". Folha de S.Paulo (in Brazilian Portuguese). Archived from the original on 14 June 2023. Retrieved 14 June 2023.
- ^ Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (July 2005). "Vaccine pharmacotherapy for the treatment of cocaine dependence". Biol. Psychiatry. 58 (2): 158–64. doi:10.1016/j.biopsych.2005.04.032. PMID 16038686. S2CID 22415520.
- ^ Hesse M (2002). Alkaloids: Nature's Curse or Blessing?. Weinheim: Wiley-VCH. p. 304. ISBN 978-3-906390-24-6.
- ^ "Drug that spans the ages: The history of cocaine". London: The Independent (UK). 2006. Archived from the original on 28 February 2010. Retrieved 30 April 2010.
- ^ Luch A (3 April 2009). Molecular, Clinical and Environmental Toxicology. Basel Boston: Springer Science & Business Media. p. 20. ISBN 978-3-7643-8336-7.
- ^ Niemann A (1860). "Ueber eine neue organische Base in den Cocablättern". Archiv der Pharmazie. 153 (2 and 3): 129–155, 291–308. doi:10.1002/ardp.18601530202. S2CID 98195820. Archived from the original on 28 July 2020. Retrieved 30 June 2019.
- ^ Harper D. "Cocaine". Online Etymology Dictionary.
- ^ Halsted W (1885). "Practical comments on the use and abuse of cocaine". New York Medical Journal. 42: 294–295.
- ^ Corning JL (1885). "An experimental study". New York Medical Journal. 42: 483.
- ^ Lien N, Feltran G (11 March 2025). "(I)llicit Chains: Some New Hypotheses Regarding a Changing Global Cocaine Market". Journal of Illicit Economies and Development. 7 (1): 20–34. doi:10.31389/jied.274. ISSN 2516-7227.
- ^ "Cocaine". American Heritage Dictionary. Archived from the original on 3 January 2023. Retrieved 3 January 2023.
Further reading
[edit]- Spillane JF, ed. (2000). Cocaine: From Medical Marvel to Modern Menace in the United States, 1884–1920. Baltimore and London: The Johns Hopkins University Press. ISBN 978-0-8018-6230-4.
- Feiling T (2009). The Candy Machine: How Cocaine Took Over the World. London: Penguin. ISBN 978-0-14-103446-1.
- Gewin V (2 November 2011). "Smoking stokes cocaine cravings: Molecular mechanism found for controversial 'gateway drug' hypothesis". Nature News. doi:10.1038/news.2011.627.
- "Global Report on Cocaine 2023" (PDF). United Nations Office on Drugs and Crime (UNODC).
External links
[edit]Cocaine
View on GrokipediaNatural Sources and Traditional Use
The Coca Plant
The coca plant belongs to the genus Erythroxylum in the family Erythroxylaceae, with the two primary cultivated species being Erythroxylum coca (including varieties such as Huánuco and Bolivian) and Erythroxylum novogranatense (including Colombian and Truxillo varieties).[8] These species are perennial shrubs native to the Andean regions of South America, particularly the moist inter-Andean valleys and lower eastern slopes of the Andes in countries including Peru, Bolivia, Colombia, Ecuador, and northern Argentina, where they thrive at elevations between 500 and 2,000 meters above sea level.[9] [10] The plants typically reach heights of 2 to 3 meters, featuring smooth bark, slender branches, and small, alternate, elliptical leaves that are 3-7 cm long and contain the tropane alkaloids responsible for their pharmacological properties.[11] Cocaine constitutes the principal alkaloid in coca leaves, accounting for 0.5% to 1.0% of the dry leaf weight, though measurements in E. coca var. coca have ranged from 0.23% to 0.96%.[12] [8] Accompanying alkaloids include ecgonine, benzoylecgonine, and tropacocaine, among at least 14 other minor tropane, pyrrolidine, and pyridine derivatives that together comprise up to 2% total alkaloids by dry weight.[11] [8] Alkaloid concentrations vary by variety, climate, soil conditions, leaf age, and harvest time, with Bolivian coca averaging around 0.63% cocaine.[13] In their natural form, coca leaves provide mild stimulation when chewed in low doses, as practiced traditionally in the Andes, yielding benefits such as reduced hunger, thirst, and fatigue, improved tolerance to high-altitude hypoxia, and supplemental nutrition from contained vitamins (e.g., riboflavin, vitamin C) and minerals (e.g., calcium, iron, phosphorus).[12] [8] Unlike purified cocaine, habitual ingestion of unprocessed leaves does not produce addiction or significant mental and physical harm, as evidenced by long-term Andean use patterns and assessments finding no toxicomania but rather a cultural habit.[14] [15] This contrasts with the risks of concentrated extraction, attributable to the leaves' low alkaloid yield and presence of buffering compounds that mitigate acute effects.[12]Indigenous Andean Practices
Archaeological evidence from Peru's Nanchoc Valley reveals that indigenous foraging societies began chewing coca leaves around 8000 years ago, as indicated by residues of coca and calcite (used to enhance alkaloid extraction) found in ancient house floors.[16] This practice likely aided labor endurance in demanding activities such as mining and high-altitude agriculture, where the leaves' mild stimulant effects—derived from low concentrations of cocaine alkaloids (typically 0.5-1% by dry weight)—helped mitigate fatigue, hunger, and hypoxia without the rapid intoxication of isolated extracts.[8] In Inca society, from the 15th century onward, coca consumption expanded from elite rituals to integral social, physiological, and medicinal roles, distributed by the state to laborers in the mit'a corvée system for tasks like terrace farming and silver mining at Potosí.[8] Leaves were masticated with an alkaline additive such as llipta (a paste of burned shells or plant ash), which raised oral pH to liberate alkaloids for buccal absorption, enabling sustained low-level stimulation that supported productivity and social cohesion without fostering dependence, as evidenced by the absence of withdrawal syndromes in chronic users.[12] Ritually, coca bundles (k'intu) symbolized offerings to deities, integrating the plant into cosmology as a divine gift for endurance and reciprocity (ayni).[17] Epidemiological observations among Andean populations, where up to 10-20% of adults traditionally chew coca daily, demonstrate negligible addiction liability from leaf use, contrasting sharply with purified cocaine's high abuse potential due to its concentrated delivery (yielding blood cocaine levels up to 50 times higher) and blockade of dopamine reuptake transporters, which causally drives reinforcement and tolerance.[8] A 1995 World Health Organization assessment of global coca leaf studies found no significant mental or physical health damage from traditional consumption, attributing benefits like altitude acclimatization and appetite suppression in nutrient-scarce environments to synergistic leaf compounds beyond cocaine alone.[14] While some correlations exist with malnutrition or dental wear in isolated cohorts, these lack causal attribution to coca—often confounded by poverty—and pale against cocaine's documented neurotoxicity, cardiovascular risks, and 15-20% dependence rate among recreational users.[18][19] This distinction underscores how extraction isolates the alkaloid's euphoriant effects, amplifying harm through pharmacokinetic shifts absent in holistic leaf practices.Biosynthesis and Chemistry
Biosynthetic Pathway
Cocaine biosynthesis occurs primarily in the young leaves and apical buds of Erythroxylum coca, involving a specialized tropane alkaloid pathway that incorporates unique enzymes diverging from those in Solanaceae plants. The process yields cocaine at concentrations of 0.5–1.0% by dry leaf weight, with variations by cultivar such as 0.66% in E. coca var. coca and 1.04% in var. novogranatense.[12][20] This natural efficiency underpins the economic dominance of leaf extraction over total chemical synthesis, which requires lengthy routes (e.g., 25+ steps in early methods) plagued by low yields, stereochemical complexity, and high costs, making it impractical for large-scale production.[21][22] The pathway initiates from the amino acids ornithine or arginine, which are decarboxylated to putrescine by ornithine decarboxylase (ODC; EcODC) or arginine decarboxylase (ADC; EcADC), respectively—the first committed step localized to leaf tissues.[23] Putrescine is then converted to spermidine by the bifunctional enzyme EcSPMT (spermidine synthase/N-methyltransferase), utilizing both S-adenosylmethionine (SAM) and decarboxylated SAM (dcSAM). Spermidine undergoes N-methylation to N-methylspermidine via EcSMT (spermidine N-methyltransferase), followed by oxidative cleavage by flavin-dependent EcAOF1 to regenerate N-methylputrescine. This is further oxidized by copper-dependent amine oxidases EcAOC1/2 to form the key intermediate N-methyl-Δ¹-pyrrolinium (NMPy).[24] NMPy condenses with 2-oxoglutarate in a reaction catalyzed by EcOGAS1/2 (3-oxoglutarate synthases), yielding methyl pseudotropyl-β-ketone (MPOB), which incorporates the tropane ring scaffold. MPOB is methylated by SABATH-family EcMPOBMT to methyl pseudotropyl-methyl-β-ketone (MPMOB), preserving the 2-carbomethoxy group essential for cocaine. Oxidative cyclization of MPMOB to methylecgonone is mediated by cytochrome P450 EcCYP81AN15, a discovery highlighting Erythroxylaceae-specific innovations. Methylecgonone is then reduced to methylecgonine by EcMecgoR (methylecgonone reductase), and finally benzoylated with benzoyl-CoA by BAHD acyltransferase EcCS (cocaine synthase) to produce cocaine.[24][25] Genes encoding these enzymes exhibit tissue-specific expression, peaking in developing leaves (L1/L2 stages) and buds, which correlates with alkaloid accumulation and suggests regulatory control by developmental cues rather than broad environmental stressors. Recent genetic engineering has reconstructed the full pathway in heterologous hosts like Nicotiana benthamiana, achieving de novo cocaine production and enabling hybrid tropane alkaloid synthesis, with potential applications for engineering coca variants with altered alkaloid profiles to reduce narcotic content while retaining other metabolites.[24][25][26]Chemical Properties and Forms
Cocaine, chemically known as methyl (1R,2R,3S,5S)-8-methyl-3-(benzoyloxy)-8-azabicyclo[3.2.1]octane-2-carboxylate, is a tropane alkaloid with the molecular formula C₁₇H₂₁NO₄ and a molecular weight of 303.358 g/mol.[1] Its structure includes a bicyclic tropane ring system esterified with benzoic acid and a methyl carboxylate group, enabling rapid penetration of biological membranes.[27] The primary pharmaceutical and illicit form is cocaine hydrochloride, a water-soluble salt appearing as a white crystalline powder that is highly soluble in water (exceeding 1 g per 0.5 mL), facilitating routes like intranasal or parenteral administration. It is hygroscopic, meaning it absorbs moisture from the atmosphere, which can cause clumping or a sticky texture in humid environments, such as inside a vehicle during warm weather.[28] Cocaine hydrochloride does not spontaneously convert to its freebase form (crack cocaine) when left exposed to air, heat, or humidity. Such conversion requires intentional processing with a base like sodium bicarbonate or ammonia, followed by heating to produce solid rocks. Under prolonged high temperatures (e.g., in a hot car), it may experience gradual degradation and weight loss, with formation of volatile byproducts like methyl benzoate in the presence of humidity, but no crack formation occurs. In contrast, the freebase form lacks the hydrochloride ion, rendering it insoluble in water (approximately 1 g per 600 mL) but volatile with a low melting point around 98°C, suitable for vaporization and inhalation via smoking. Crack cocaine represents a smokable variant of the freebase, formed by neutralizing cocaine hydrochloride with sodium bicarbonate to yield rock-like chunks that decompose at higher temperatures without significant thermal breakdown until inhalation.[29][29] Street cocaine, predominantly the hydrochloride form, frequently contains adulterants such as levamisole, an anthelmintic agent detected in 69% of U.S. cocaine samples entering the country as reported by the DEA in assessments up to 2010, with persistence noted in subsequent analyses.[30] Cocaine exhibits chemical instability, undergoing hydrolysis of its ester linkages in the presence of moisture, accelerated by light and elevated temperatures above 350°C, which promotes degradation into ecgonine methyl ester and benzoic acid, thereby necessitating adulteration in illicit markets to maintain apparent potency.[31][32]Synthesis and Production Methods
The first total synthesis of cocaine was accomplished by Richard Willstätter in 1898 through a multi-step process starting from tropinone, involving over 20 reactions that confirmed the alkaloid's structure but rendered it commercially unviable due to low yields and high complexity.[33] Subsequent total syntheses, such as those simplified in the 1980s to 3-5 steps from racemic 2-carbomethoxytropinone, remain impractical for large-scale production owing to the need for chiral resolution and inefficient stereoselectivity.[34] Pharmaceutical production of cocaine hydrochloride for medical use does not employ total synthesis; instead, it involves extraction and purification of the alkaloid directly from coca leaves sourced from licensed plantations in Peru and Bolivia, followed by conversion to the hydrochloride salt in regulated facilities, primarily in the United States and Europe.[35] This semi-synthetic approach from natural ecgonine precursors—via benzoylation to benzoylecgonine and methylation—ensures high purity but is tightly controlled under international treaties, yielding pharmaceutical-grade product at efficiencies far superior to illicit methods.[36] Illicit production predominantly extracts cocaine from coca leaves through a rudimentary process: leaves are macerated and treated with kerosene or gasoline to solubilize alkaloids, followed by acidification with dilute sulfuric acid to form water-soluble cocaine sulfate, filtration, and basification with ammonia or sodium carbonate to precipitate crude cocaine base (pasta básica or coca paste).[36] This base is then purified via acetone or ether extraction, oxidized with potassium permanganate to remove impurities, and converted to cocaine hydrochloride by gassing with hydrogen chloride, achieving overall yields of about 0.5-1% cocaine from dry leaf mass due to losses in crude extraction and impurities like cinnamoylcocaine.[37] Field testing for purity often employs colorimetric reagents or thin-layer chromatography kits to detect adulterants, though these methods lack the precision of laboratory gas chromatography-mass spectrometry.[36] Research into biosynthetic engineering has reconstructed parts of the cocaine pathway in yeast, enabling de novo production of tropane alkaloids and hybrid analogs, but full cocaine titers remain low (microgram-scale per liter) as of 2022, limited by enzyme efficiency and precursor flux, positioning it as a proof-of-concept rather than a viable alternative to extraction.[38] These microbial approaches aim to bypass plant cultivation vulnerabilities but face scalability challenges compared to traditional methods.[39]Pharmacology
Mechanism of Action
Cocaine is a highly potent CNS stimulant, ranked above amphetamine in intensity of effects but acting via dopamine reuptake inhibition rather than release, producing rapid intense euphoria with shorter duration and listed among the strongest stimulants overall. Cocaine primarily acts as a competitive inhibitor of the dopamine transporter (DAT), blocking the reuptake of dopamine from the synaptic cleft into presynaptic neurons, which results in elevated extracellular dopamine concentrations in key brain regions such as the nucleus accumbens.[40][41] This inhibition occurs with a binding affinity (Ki) of approximately 0.5–0.6 μM at DAT, leading to prolonged dopamine signaling at postsynaptic receptors and contributing to the drug's reinforcing properties through enhanced activation of the mesolimbic reward pathway.[42] Cocaine similarly inhibits the norepinephrine transporter (NET) and serotonin transporter (SERT), albeit with lower potency (Ki values around 0.3 μM for NET and 1–2 μM for SERT), elevating levels of these monoamines and amplifying sympathetic arousal and mood alterations.[40] These mechanisms distinguish cocaine, a stimulant derived from coca leaves, from opioids such as heroin, which is derived from morphine obtained from the opium poppy and primarily binds to mu-opioid receptors in the brain after rapid conversion to morphine, producing intense euphoria followed by drowsiness, slowed breathing and heart rate, clouded mental functioning, and pain relief. Cocaine's primary effects include intense short-term euphoria, increased energy, alertness, talkativeness, and elevated heart rate and blood pressure, with durations typically lasting 5-30 minutes depending on the route of administration, in contrast to heroin's effects which last 3-5 hours.[43][44] Both drugs share common routes of administration, including snorting, smoking, and injection, though heroin is frequently injected intravenously.[43][44] The reinforcing effects are causally linked to dopamine accumulation in the nucleus accumbens, as evidenced by positron emission tomography (PET) studies in humans and rodents showing dose-dependent increases in extracellular dopamine following cocaine administration, with peak elevations correlating to behavioral reinforcement in self-administration paradigms.[45][46] At low doses (e.g., 10–30 mg in humans), this manifests as heightened dopaminergic transmission without immediate toxicity, whereas higher doses (e.g., >50 mg) saturate transporters, prolonging dopamine exposure and escalating risk of neurotoxicity via oxidative stress from excess cytosolic dopamine.[47] Animal microdialysis data confirm that cocaine-induced dopamine levels in the nucleus accumbens can rise 3- to 5-fold above baseline, directly driving operant responding for the drug.[48] In addition to its monoamine reuptake inhibition, cocaine functions as a local anesthetic by binding to voltage-gated sodium channels in their open and inactivated states, thereby stabilizing the inactivated conformation and preventing sodium influx necessary for action potential propagation.[49][3] This blockade, akin to that of other local anesthetics like lidocaine, occurs at the inner pore of the channel with micromolar affinity and underlies cocaine's utility in medical settings for topical anesthesia, though systemic administration at recreational doses often leads to cardiotoxic effects from widespread neuronal and cardiac sodium channel inhibition.[49] Empirical patch-clamp studies demonstrate use-dependent blockade, where repetitive neuronal firing enhances cocaine's inhibitory potency, contributing to both therapeutic numbing and pathological conduction delays.[50]Pharmacokinetics and Metabolism
Cocaine exhibits rapid absorption, distribution, metabolism, and elimination, with pharmacokinetics varying significantly by route of administration. Intravenous administration yields 100% bioavailability, with peak plasma concentrations achieved within seconds to minutes due to direct entry into the systemic circulation.[2] Intranasal insufflation results in bioavailability of approximately 60-80%, with absorption occurring primarily through the nasal mucosa; however, local vasoconstriction induced by cocaine itself limits uptake, leading to peak plasma levels in 15-60 minutes.[2][3] Smoked cocaine (as the freebase form) achieves high bioavailability exceeding 70-90% via pulmonary absorption, with rapid onset comparable to intravenous use, peaking in 1-5 minutes.[2] Oral ingestion, in contrast, demonstrates lower bioavailability of 20-40% owing to extensive hydrolysis by gastrointestinal and hepatic esterases during first-pass metabolism, resulting in delayed absorption and peak concentrations within 1-2 hours.[51][52] Distribution of cocaine is widespread and rapid, with a volume of distribution of 1-3 L/kg, reflecting extensive tissue penetration including the central nervous system due to its lipophilicity and ability to cross the blood-brain barrier.[2] Approximately 90% of circulating cocaine binds to plasma proteins such as albumin and alpha-1-acid glycoprotein, influencing free drug availability for pharmacological effects.[2] Metabolism occurs predominantly via enzymatic hydrolysis by plasma pseudocholinesterase and hepatic carboxylesterases, yielding major inactive metabolites benzoylecgonine (BE) and ecgonine methyl ester (EME), which account for over 90% of biotransformation.[51][2] Minor pathways produce norcocaine (active and hepatotoxic) and, in the presence of ethanol, cocaethylene (longer-acting and more cardiotoxic).[51] The elimination half-life of unchanged cocaine averages 0.5-1.5 hours, varying by route—shorter with intravenous or smoked administration (around 40 minutes) and slightly prolonged with intranasal or oral routes.[2] Excretion is primarily renal, with less than 10% of the parent drug eliminated unchanged and the remainder as metabolites; urinary pH influences reabsorption, with acidic conditions enhancing clearance.[2] Pharmacokinetic variability is influenced by factors such as route-specific absorption kinetics, which predict onset and duration for risk assessment: rapid routes like intravenous or inhalation heighten acute overdose potential due to swift peak effects, while slower oral uptake prolongs exposure but reduces intensity.[2] Adulterants (e.g., local anesthetics or alkaloids) can alter mucosal absorption rates or stability, and gastric pH affects oral bioavailability by impacting ionization and hydrolysis.[2] BE exhibits a longer half-life (up to several hours), contributing to sustained systemic presence post-cocaine clearance.[2]Detection in Biological Samples
Cocaine and its primary metabolite, benzoylecgonine (BE), are detectable in various biological matrices, with methods varying by sample type to assess recent versus historical exposure. Urine testing predominates in clinical and forensic contexts due to its non-invasiveness and extended detection window, employing initial enzyme-linked immunosorbent assays (ELISA) or immunoassay screens for presumptive positives, confirmed via gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) for specificity.30825-4/fulltext)[53] Blood and oral fluid (saliva) analyses target parent cocaine for acute use, using similar chromatographic techniques, while hair testing leverages segmental analysis to reveal patterns of chronic ingestion over months.[54] These approaches prioritize sensitivity thresholds, such as 150 ng/mL for urine BE in federal workplace guidelines, though cutoffs vary by jurisdiction and purpose.[55] Detection windows depend on dose, frequency, individual metabolism, hydration, and body mass, with single-use scenarios yielding shorter intervals than chronic exposure. There is no safe, reliable, or scientifically proven method to significantly accelerate the elimination of cocaine or its metabolites from the body.[56] Clearance occurs naturally through hepatic metabolism and renal excretion, with factors such as hydration, exercise, or pH alteration having minimal impact and potentially risking detection of tampering in tests. Commercial detox kits and home remedies are ineffective, unregulated, and may cause harm like dehydration or electrolyte imbalances without altering test outcomes reliably.[57] The recommended approach for those concerned about detection or dependence is abstinence and, if needed, professional medical evaluation for addiction treatment. In urine, BE is detectable 2–4 days post-single use but up to 10–22 days in heavy users, reflecting renal clearance half-life of approximately 6 hours for cocaine and 12 hours for BE.[55] Blood concentrations of cocaine peak within minutes of administration and decline to undetectable levels within 12–48 hours, suitable for correlating with impairment but limited by rapid distribution.[58] Oral fluid mirrors blood kinetics, detecting cocaine for 1–2 days after a 100 mg dose, with BE appearing later and persisting similarly, advantageous for roadside testing due to supervised collection.[54] Hair incorporates cocaine via sweat and sebum, enabling detection up to 90 days, though external contamination risks necessitate washing protocols and isotopic ratio analysis for verification.[59]| Biological Sample | Primary Analyte | Typical Detection Window (Single Use) | Notes |
|---|---|---|---|
| Urine | Benzoylecgonine | 2–4 days | Extends to weeks with chronic use; most common for compliance monitoring.[55] |
| Blood | Cocaine | 12–48 hours | Indicates recent intake; plasma preferred over serum for accuracy.[58] |
| Oral Fluid | Cocaine/BE | 1–2 days | Useful for acute detection; collection devices standardize volumes.[54] |
| Hair | Cocaine/BE | Up to 90 days | 1 cm segment ≈1 month; decontamination essential to exclude environmental exposure.[59] |
Medical Applications
Historical Therapeutic Uses
Cocaine was isolated in pure form by German chemist Albert Niemann in 1860 from Erythroxylum coca leaves, enabling its extraction for medical experimentation.[67] In the ensuing decades, it gained prominence as a therapeutic agent due to its stimulant effects and vasoconstrictive properties, prescribed for conditions including fatigue, digestive issues, seasickness, hay fever, sinusitis, toothache, sore throats, coughs, and respiratory congestion from colds or influenza.[68][69] It appeared in patent medicines, tonics, and beverages, including cocaine lozenges, throat sprays, and toothache drops marketed for numbing relief in these ailments; for instance, the original Coca-Cola syrup, formulated by John Pemberton in 1886, incorporated cocaine derived from coca leaf extract as a purported brain tonic until its removal by 1903 amid growing concerns over unregulated use.[70][71][72] A pivotal advancement occurred in 1884 when Austrian ophthalmologist Karl Koller empirically tested cocaine's numbing effects on the eye, applying a 2-4% solution to anesthetize the cornea and conjunctiva, thereby facilitating painless intraocular surgeries such as iridectomies and cataract extractions without general anesthesia.[67][73] This discovery marked cocaine as the first effective local anesthetic, rapidly adopted in surgical practice for its ability to block nerve conduction while constricting blood vessels to reduce bleeding. Sigmund Freud, in his 1884 monograph Über Coca, strongly endorsed its virtues based on self-experimentation and clinical observations, praising it for treating depression, fatigue, and morphine addiction (though he later recognized its risks), while noting its capacity to counteract sedation and enhance mental clarity without inducing tolerance in moderate doses.[74][75] Despite these endorsements, empirical evidence of risks surfaced concurrently; reports from the 1880s documented cases of poisoning, including animal studies in The Lancet highlighting lethal doses, and human instances of toxicity by 1885.[76] By the 1890s, clinical observations linked chronic use to dependence, manifesting in paranoia, insomnia, malnutrition, and nasal damage, with U.S. case reports associating cocaine with violent incidents such as murders, underscoring its potential for habituation despite therapeutic benefits.[77][78] These early warnings contrasted initial optimism, revealing cocaine's dual nature as both efficacious stimulant and nascent public health concern prior to regulatory interventions.Current Approved Indications
Cocaine hydrochloride is approved by the United States Food and Drug Administration (FDA) solely for topical application as a local anesthetic to mucous membranes, particularly in ear, nose, and throat (ENT) procedures. The approved formulation, such as Goprelto 4% nasal solution, is indicated for inducing anesthesia of the nasal mucosa prior to diagnostic procedures or surgery, leveraging its dual properties of anesthesia and vasoconstriction to facilitate visualization and reduce bleeding.[79][80] No systemic or injectable approvals exist due to the drug's high potential for abuse and associated cardiovascular risks.[3] In Europe, the European Medicines Agency (EMA) does not list specific centralized approvals for cocaine as a medicinal product, though national authorizations permit its limited use as a topical anesthetic in similar contexts, often under strict controls reflecting abuse liability concerns.[81] Typical concentrations range from 4% to 10% solutions applied via pledgets or sprays, with a maximum recommended dose of 1.5 to 3 mg/kg or 200 mg total to minimize systemic absorption.[82] Compared to alternatives like lidocaine, cocaine demonstrates equivalent anesthetic efficacy but superior hemostasis in nasal procedures due to inherent vasoconstrictive effects, though lidocaine combined with epinephrine or oxymetazoline can achieve comparable outcomes with lower toxicity risks.[83][84] Contraindications include hypersensitivity to cocaine, severe cardiovascular disease, and glaucoma, as the drug's sympathomimetic actions can precipitate hypertension, arrhythmias, or increased intraocular pressure.[3] Use during pregnancy is cautioned (FDA Pregnancy Category C), with potential fetal risks including vasoconstriction-induced placental insufficiency, though controlled topical doses limit systemic exposure.[85] In patients with heart disease, alternatives are preferred to avoid exacerbating ischemia or arrhythmias.[86] Pediatric applications are restricted to lowest effective doses (1-4% concentrations) under close monitoring, with evidence indicating safety for brief ENT interventions when absorption is minimized, though non-cocaine anesthetics are often favored to mitigate seizure or toxicity risks from inadvertent overdose.[87][88]Emerging Research and Potential Therapies
Research into monoclonal antibodies for cocaine overdose reversal has demonstrated potential in preclinical models, where antibodies such as GNCgzk bind cocaine to prevent its entry into the brain, reducing acute toxicity and lethality in animal studies.[89] However, clinical translation remains limited, with no large-scale human trials reported as of 2024; earlier passive immunization approaches showed promise but highlighted challenges in achieving sufficient antibody titers for therapeutic efficacy.[90] A 2024 preclinical study identified carnosic acid, an antioxidant in rosemary extract, as capable of reducing volitional cocaine intake in mice by modulating activity in the globus pallidus externus, a brain region linked to reward processing, without altering general locomotor behavior.[91] This effect was mediated by dampening parvalbumin neuron hyperactivity induced by cocaine, suggesting a targeted mechanism for curbing addiction-related behaviors, though human applicability requires further validation beyond rodent models.[92] Cocaine vaccine candidates, such as TA-CD, which conjugates cocaine analogs to cholera toxin B subunit to elicit antibodies that sequester the drug, advanced to phase II trials but failed to achieve primary endpoints for abstinence, leading to termination of phase III development.[93] Newer iterations, including dAd5GNE, have shown preclinical advancements in antibody production but lack recent clinical data, underscoring persistent hurdles in immunogenicity and individual response variability.[94] Meta-analyses of modafinil for cocaine dependence indicate mixed results, with no overall superiority over placebo for abstinence or retention in randomized trials, though subgroup analyses from U.S. studies suggest modest benefits in reducing use among certain populations.[95] These findings align with its mechanism as a weak dopamine reuptake inhibitor promoting wakefulness, potentially aiding withdrawal symptoms like fatigue, but efficacy is inconsistent, particularly in methadone-maintained patients.[96] Exploratory research into cocaine's interactions with ADHD has tested stimulants like methylphenidate in comorbid cases, showing safety at supratherapeutic doses but no consistent reduction in cocaine use, with trials emphasizing the need for integrated behavioral therapies. Cocaine itself does not provide sustained therapeutic benefits for ADHD symptoms; although it may temporarily mimic stimulant effects by enhancing dopamine availability, studies indicate it ultimately worsens attention, working memory, impulse control, and overall brain function, alongside high risks of addiction, cardiovascular damage, and overdose.[97][98] Neuroprotection studies reveal cocaine's paradoxical enhancement of taurine release post-withdrawal, which may mitigate excitotoxicity, but this does not translate to therapeutic strategies and highlights risks of neuroadaptation rather than protective interventions.[99] Overall, high failure rates in clinical endpoints for pharmacological and immunotherapeutic approaches underscore the dominance of behavioral and contingency management in current evidence-based treatments.Recreational and Illicit Use
Routes of Administration
Cocaine hydrochloride powder is most commonly administered via insufflation, in which the substance is snorted into the nasal mucosa, achieving bioavailability of approximately 30 to 60 percent due to partial absorption through the nasal lining and some gastrointestinal uptake from post-nasal drip. Snorting cocaine initially causes nasal dryness, numbness, and sore nasal passages due to vasoconstriction, irritation, inflammation, burning pain, and chronic damage to nasal tissues.[100] As the effects wear off, rebound inflammation and increased mucus production often lead to a runny nose with possible yellow or purulent discharge, nasal drip, or post-nasal drip (known as "cocaine drip"), particularly when secondary sinus infections develop from impaired drainage, tissue necrosis, and chronic inflammation, which may be felt in the throat during or after the high.[101][100] Onset of effects occurs within 1 to 5 minutes, with peak plasma concentrations reached in 15 to 30 minutes and effects lasting 20 to 60 minutes, influenced by dose and individual factors.[102] This route exposes users to adulterants common in street powder, such as levamisole or fentanyl, which can exacerbate nasal tissue damage and systemic toxicity, though empirical data on route-specific purity variations remain limited in recent global assessments.[2] [103] Intravenous injection delivers nearly 100 percent bioavailability, with onset in seconds and effects persisting for 5 to 15 minutes, enabling rapid escalation to high doses and heightened overdose risk.[104] Shared needles and equipment in this method substantially elevate transmission of HIV and hepatitis C, with studies linking injection drug use, including cocaine, to clusters of HIV infections among people who inject drugs.[105] [106] Harm reduction data indicate that needle-sharing practices persist despite availability of sterile equipment, contributing to ongoing infectious disease burdens in affected populations.[107] Smoking freebase cocaine, typically as crack, yields bioavailability of 70 to 90 percent through pulmonary absorption, with onset under 10 seconds and brief duration of 5 to 10 minutes, promoting rapid redosing.[2] This route minimizes gastrointestinal first-pass metabolism but introduces respiratory tract exposure to pyrolysis byproducts and potential contaminants from impure sourcing, though crack forms often exhibit higher effective purity compared to powdered variants in illicit markets.[108] Equipment such as pipes can harbor residues, increasing risks of oral and lung irritation over repeated use.| Route | Bioavailability | Onset | Duration | Key Risks |
|---|---|---|---|---|
| Insufflation | 30-60% | 1-5 min | 20-60 min | Adulterant absorption, nasal damage |
| Injection | ~100% | Seconds | 5-15 min | HIV/HCV transmission, overdose |
| Smoking (crack) | 70-90% | <10 sec | 5-10 min | Respiratory exposure, rapid cycling |
| Oral mucosal (gumming) | 30-50% | 10-45 min | 15-120 min | Oral ulceration, gum recession, enamel erosion, "coke mouth" |
Subjective and Behavioral Effects
Cocaine induces a range of acute subjective effects, primarily characterized by intense euphoria, often described as a powerful "rush" especially when snorted or smoked, heightened alertness, increased energy, confidence, talkativeness, sociability, heightened motivation, reduced inhibitions, and enhanced sexual pleasure, as reported in self-administration studies using visual analogue scales to quantify user experiences.[109] [110] Users often describe reduced fatigue, enhanced talkativeness, and appetite suppression, with these sensations peaking within minutes of administration via routes such as intranasal or intravenous delivery and typically lasting 15-90 minutes depending on dose and route, often prompting redosing that escalates negative effects.[111] These effects correlate with dose-dependent blockade of dopamine transporters, contributing to the rapid onset of perceived reward.[112] Behavioral pharmacology demonstrates cocaine's strong reinforcing properties through self-administration paradigms, where nonhuman primates and humans repeatedly lever-press or perform tasks to obtain doses, reflecting its high incentive salience independent of initial novelty.[113] [114] This reinforcement is evident across species, with escalating response rates under progressive-ratio schedules, indicating motivation to sustain access despite increasing effort costs.[115] Higher doses shift subjective reports toward negative states, including anxiety, paranoia (especially at higher doses or with repeated use), restlessness, insomnia, jaw clenching, following inverted U-shaped dose-response curves observed in controlled human laboratory settings, with severe comedowns characterized by depression, fatigue, and irritability alongside strong cravings that promote binge use.[116] Individual variability in these responses is substantial, influenced by genetic factors such as polymorphisms in dopamine-related genes and rapid tolerance development, which diminishes euphoric intensity with repeated exposure.[117] [118] Longitudinal cohort studies refute uniform "gateway" characterizations of cocaine, showing that progression to or from its use depends on multifactorial influences like age of onset and comorbid traits rather than deterministic sequencing, with many users not advancing to polysubstance patterns.[119] This variability underscores that behavioral reinforcement and subjective appeal do not predictably escalate to broader dependency trajectories across populations.[120] Harm reduction guidelines emphasize that there is no safe amount of cocaine per session, as even single or small doses carry significant risks including sudden cardiac arrest, stroke, addiction potential, and overdose, particularly due to frequent adulteration with fentanyl or other substances.[121] Precautions include testing substances for fentanyl using test strips, starting with very small doses and proceeding slowly, avoiding mixing with alcohol which produces the more toxic cocaethylene, not using alone to allow for emergency assistance, and seeking professional help for dependency concerns.[122][123]Global Prevalence and Recent Trends
In 2023, an estimated 25 million people aged 15-64 used cocaine globally, marking an increase from 17 million users a decade earlier, according to the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2025.[124] This figure represents the highest recorded prevalence to date, driven primarily by expanded production in South America, which reached a record 3,708 tons in 2023.[125] In the United States, past-year cocaine use among individuals aged 12 and older stood at 1.8%, or approximately 5 million people, in 2023, as reported by the National Survey on Drug Use and Health (NSDUH).[126] Use rates were highest among young adults aged 18-25, at 4.6%, reflecting a demographic concentration in this group.[127] Trends indicate a shift toward powder cocaine over crack, with overall cocaine submissions increasingly adulterated with fentanyl in one out of every eight law enforcement samples analyzed by the Drug Enforcement Administration (DEA) in 2024, highlighting rising polydrug combinations involving opioids.[128] In Europe, wastewater analysis by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) revealed surges in cocaine residues, with 39 out of 72 monitored cities reporting higher levels in 2024 compared to 2023, particularly in western and southern regions.[129] In the United Kingdom, cocaine-involved deaths registered in 2024 totaled 1,279, a 14.4% increase from the prior year, per Office for National Statistics (ONS) data, underscoring escalating harms amid stable or rising consumption patterns.[130] These trends align with broader global patterns of intensified supply and polydrug integration, though crack cocaine use appears to be declining relative to powder forms in markets like the US.[131]Physiological Effects
Acute Physiological Responses
Cocaine administration triggers rapid sympathomimetic responses primarily through inhibition of norepinephrine reuptake, elevating sympathetic nervous system activity and resulting in tachycardia, with heart rates often increasing by 20-50 beats per minute depending on dose and route.[132] This is accompanied by hypertension, where systolic blood pressure may rise 10-25% above baseline in early toxicity stages due to enhanced myocardial contractility and vascular tone.[133] Hyperthermia ensues from increased metabolic demand, reduced peripheral vasodilation, and central thermoregulatory disruption, potentially elevating core body temperature by 1-2°C and exacerbating risks like rhabdomyolysis.[134] Vasoconstriction, mediated by alpha-adrenergic stimulation from accumulated catecholamines, narrows coronary and cerebral arteries, heightening ischemia risk even in young users without preexisting disease; this effect is dose-dependent and persists briefly post-use.[135] Appetite suppression occurs via elevated dopamine signaling in hypothalamic feeding centers, inhibiting neuropeptides like neuropeptide Y and promoting anorectic pathways such as those involving cocaine- and amphetamine-regulated transcript (CART).[136] Empirical evidence from positron emission tomography (PET) imaging correlates hypothalamic activation patterns with reduced hunger perception following acute exposure, distinct from cue-induced responses in dependent users.[137] Clinical studies reveal sex differences in these responses, with women often exhibiting higher plasma cocaine concentrations and amplified cardiovascular effects—such as greater blood pressure elevations—for equivalent doses, influenced by menstrual cycle phase and pharmacokinetic variances like slower hepatic metabolism.[138] These disparities underscore causal roles of estrogen in modulating monoamine transporter sensitivity, leading to potentially heightened acute risks in females despite lower typical consumption volumes.[139]Chronic Physiological Changes
Chronic intranasal administration of cocaine induces vasoconstriction and ischemia in nasal mucosa, leading to progressive necrosis and eventual perforation of the nasal septum, a condition documented in clinical examinations of habitual users. Autopsy studies and otolaryngological reports confirm that this erosion, often termed "cocaine nose," results from repeated exposure to the drug's sympathomimetic effects, with perforations ranging from small defects to complete septal collapse observed in up to 20-30% of chronic snorters in case series.[140] [141] Prolonged cocaine use also causes gingival recession and periodontal tissue damage, particularly when the drug is applied directly to oral mucosa or smoked as crack, promoting xerostomia, which reduces saliva flow and enables bacterial overgrowth that produces odors leading to halitosis; this dryness and resultant bad breath are intensified by dehydration from inadequate water intake, alongside erosive lesions. Epidemiological surveys of substance abusers reveal heightened rates of gingival ulceration and attachment loss, with integrative reviews identifying these changes as direct consequences of cocaine's local vasoconstrictive and irritant properties, exacerbating tooth mobility and bone loss in affected individuals.[142] [143][144] Sustained cocaine exposure contributes to significant weight loss and malnutrition through appetite suppression, elevated metabolic rate, and disrupted energy homeostasis, as evidenced by lower body mass indices in chronic users compared to non-users in cohort studies. This catabolic state arises from cocaine's interference with leptin signaling and increased lipolysis, leading to deficits in essential nutrients and muscle wasting documented via anthropometric assessments in addicted populations.[145] [146] Chronic use suppresses immune function by altering lymphocyte subsets, including reduced natural killer cell activity and imbalances in T-cell populations, increasing susceptibility to infections as shown in immunological assays of users. Data from in vivo studies indicate dose-dependent inhibition of cell-mediated immunity, with suppressed cytokine production and heightened inflammatory markers persisting during active use.[147] [148] Cardiovascular remodeling from prolonged cocaine exposure includes accelerated formation of coronary artery aneurysms, with angiographic evidence revealing a prevalence of 30.4% in young chronic users versus baseline rates of 0.2-10% in general populations. This structural change stems from chronic endothelial injury and shear stress from repeated vasospasm, confirmed in epidemiological analyses of cocaine-associated vasculopathy. Chronic use can also lead to bradycardia due to downregulation of beta-adrenergic receptors from prolonged exposure, contrasting with the tachycardia induced by acute use.[149] [150][151][152] Longitudinal observations indicate partial reversibility of certain physiological alterations following abstinence; for instance, immune markers such as CCL5 and IL-10 levels improve with sustained reduction in cocaine intake, suggesting recovery of cell-mediated responses in cohort follow-ups. However, structural damages like septal perforations often require surgical intervention and show limited spontaneous repair, while cardiovascular aneurysms may stabilize but persist as evidenced by imaging in abstinent former users.[153] [154]Psychological and Neurological Effects
Acute Psychological Effects
Cocaine acutely elevates extracellular levels of dopamine, norepinephrine, and serotonin by inhibiting their reuptake transporters, leading to rapid psychological stimulation characterized by euphoria, heightened alertness, and increased confidence.[41][116] Users commonly report intensified focus and reduced perceived fatigue, effects attributable to enhanced monoaminergic signaling in mesolimbic and prefrontal pathways as demonstrated in pharmacological challenge studies with dopamine agonists.[41] These adaptive responses typically onset within minutes via intranasal or intravenous routes, peaking at 15-30 minutes and lasting 20-60 minutes depending on dose and purity.[155] Higher doses shift this profile toward dysphoric states, with escalating anxiety, restlessness, and irritability emerging as norepinephrine-driven sympathetic overactivation predominates.[116] Paranoia and agitation intensify dose-dependently, often manifesting as suspicious ideation or perceptual distortions without full hallucinations in initial exposures, linked causally to excessive dopamine in limbic circuits per neuroimaging during acute administration.[116][156] Subjective reports of cognitive enhancement, such as sharpened decision-making, contrast with empirical data revealing acute impairments in impulse control and risk judgment; laboratory tasks show diminished performance in complex executive functions despite preserved simple attention, underscoring monoamine surges' preferential boost to arousal over nuanced reasoning.[157][158] This dissociation arises from dopamine's role in reward salience overriding prefrontal inhibitory controls, as evidenced in studies correlating plasma cocaine levels with elevated error rates in probabilistic gambling paradigms.[41]Long-Term Neurological Impacts
Chronic cocaine use induces structural alterations in the brain, including reduced gray matter volume and cortical thinning, particularly in frontal regions, as evidenced by magnetic resonance imaging (MRI) studies. A 2023 analysis of voxel-based morphometry data from cocaine users revealed accelerated brain aging and significant gray matter loss in prefrontal areas, correlating with duration and intensity of use.[159] Longitudinal MRI findings further demonstrate prefrontal cortex atrophy, with heavy users showing persistent volume reductions even after months of abstinence, suggesting causal links to cumulative neurotoxicity rather than premorbid traits.[160] Functional neuroimaging, including positron emission tomography (PET), indicates dopaminergic terminal damage in striatal regions, with reduced dopamine transporter (DAT) density observed in chronic users, reflecting axonal loss from excitotoxic mechanisms.[161] These changes disrupt frontostriatal circuits, impairing executive control, as confirmed by 2024 resting-state functional MRI data showing diminished connectivity between prefrontal and subcortical networks in abstinent individuals.[162] Cognitive impairments, such as deficits in working memory and decision-making, endure beyond acute intoxication, with longitudinal assessments revealing persistence for at least four weeks post-abstinence in crack cocaine users.[163] In moderate users, partial recovery occurs within one year of sustained abstinence, evidenced by improved performance on memory and executive tasks, but heavy, long-term exposure correlates with incomplete reversal and lasting vulnerabilities.[160] These outcomes underscore dose-dependent neuroplastic limits, where severe dopaminergic depletion hinders full restoration.[164] Chronic cocaine use can also produce peripheral neurological symptoms, particularly in the legs, including numbness and paresthesia (abnormal sensations such as tingling, burning, or warmth). These arise from mechanisms like vasospasm-induced limb ischemia, rhabdomyolysis leading to plexopathy, or multiple mononeuropathy, which impair nerve function and blood flow.[165][166]Psychiatric Complications
Cocaine use among chronic users is linked to the emergence of psychotic symptoms, including paranoia, auditory hallucinations, and delusions of persecution, which can closely resemble schizophrenia spectrum disorders. A meta-analysis of studies reported a prevalence of cocaine-induced psychosis ranging from 50.2% among current users to 55.6% among lifetime users, with higher rates observed in dependent individuals, such as up to 77.7% in those with moderate to severe cocaine dependence.[167][168] These symptoms often manifest during intoxication but can persist or recur in chronic patterns, potentially leading to treatment-resistant psychotic episodes that require antipsychotic intervention beyond cessation of use.[116] Depressive disorders represent another psychiatric complication, frequently arising as a rebound effect following the acute euphoric phase, where chronic users experience profound anhedonia, dysphoria, and suicidal ideation amid depleted dopamine signaling. Cohort studies indicate that cocaine users face an elevated suicide mortality risk, with hazard ratios approximately 1.35 compared to non-users, and broader reviews of substance cohorts estimating 10- to 20-fold increases in suicide deaths attributable to psychoactive drug use, including cocaine.[116][169][170] This risk persists even after accounting for partial confounders like comorbid alcohol or opioid use, though polydrug consumption in real-world settings complicates isolation of cocaine's specific contribution.[171] Attributing psychiatric complications solely to cocaine overlooks bidirectional causality evidenced by twin studies, which demonstrate shared genetic risk factors between cocaine dependence and underlying mental health vulnerabilities, such as personality traits predisposing to substance initiation.[172] For instance, genetic influences account for substantial heritability in both cocaine use disorders (up to 65-70%) and comorbid conditions like depression or antisocial traits, suggesting that pre-existing psychiatric liabilities may drive initiation and escalation of use rather than use unidirectionally causing de novo disorders.[173][118] This genetic overlap, combined with high rates of polysubstance abuse in clinical samples (e.g., 50-80% of cocaine users also using alcohol or cannabis), underscores the need for cautious interpretation of observational data linking cocaine to psychiatric outcomes, as self-selection and reverse causation likely inflate apparent causal effects.[174]Adverse Health Outcomes
Cardiovascular and Mortality Risks
Cocaine exerts profound cardiovascular effects through inhibition of norepinephrine reuptake, resulting in elevated sympathetic tone that manifests as hypertension, tachycardia, and coronary vasospasm.[175] These mechanisms precipitate acute arrhythmias, including ventricular fibrillation and sudden cardiac death, even among users without preexisting coronary artery disease.[176] Coronary vasospasm, a primary driver, can induce myocardial ischemia and infarction by reducing myocardial oxygen supply, with the relative risk of myocardial infarction rising up to 24-fold within the first hour following use.[176][177] Chronic exposure accelerates atherosclerosis, as evidenced by autopsy studies revealing advanced coronary plaque formation in young cocaine users compared to nonusers matched for age and other risk factors.[175][178] Histological analyses further document microvascular injury, myocarditis (prevalence 4-20% in fatal cases), and scattered myocardial necrosis contributing to cardiomyopathy and heart failure. Although cessation of cocaine use is essential for long-term health by halting progression and allowing partial endothelial function recovery, it does not alone repair existing structural vascular damage, such as arterial dissection, which may persist with residual risks requiring additional medical management.[175][179][180] Risk is amplified by higher doses, routes such as intravenous or smoked administration (e.g., crack cocaine), advanced age, and comorbidities like hypertension, with intranasal use still capable of triggering vasoconstriction.[177][181] Cocaine use can lead to cervical arterial dissection, involving tearing of the carotid or vertebral arteries, which may present as neck pain signaling potentially fatal stroke or infarction.[182] Intranasal administration may cause pneumomediastinum or pneumopericardium, resulting in neck or chest pain from air dissection into mediastinal or pericardial spaces.[183] Spinal cord ischemia due to vasospasm can manifest as neck or back pain indicative of infarction.[184] Extreme muscle tension from sympathomimetic overstimulation contributes to neck pain, often as part of broader acute responses that may precede severe complications.[185] Mortality from cocaine-attributable cardiovascular events remains significant, with standardized mortality ratios (SMR) for regular users estimated at 6.4, slightly exceeding that for amphetamines (SMR 6.0) in cohort studies adjusting for age and polydrug use.[186] In the United States, cocaine contributed to 9.8% of substance-related cardiovascular deaths from 1999-2019, amid a 4% annual rise in such fatalities linked to stimulants.[187] Globally, with approximately 20 million users as of 2025, sudden cardiac deaths predominate, often without identifiable autopsy pathology beyond arrhythmias, exacerbated by adulterants like fentanyl in street supplies that compound hemodynamic instability. There is no safe amount of cocaine per session, with risks of sudden cardiac arrest, stroke, and overdose persisting even from a single small dose, particularly due to adulteration with fentanyl or other substances.[188][189][190][191] These outcomes underscore cocaine's dose-dependent prothrombotic and proarrhythmic profile, independent of overdose thresholds.[179]Adulteration-Related Syndromes
Street cocaine is frequently adulterated with levamisole, an anthelmintic agent originally used in veterinary medicine, which has been detected in up to 87% of seized cocaine samples according to U.S. Drug Enforcement Administration analyses.[192] This contamination arises from supply chain practices where levamisole mimics cocaine's physical properties, allowing dilution without immediate detection by users, a practice economically incentivized by prohibition-driven price inflation that encourages traffickers to maximize volume and profit margins through cutting agents.[193] [194] Street cocaine is frequently adulterated with substances like levamisole, local anesthetics, and fillers. While some users attempt purification via "acetone wash" — mixing the powder with anhydrous acetone to dissolve soluble cuts while cocaine hydrochloride remains largely insoluble — this method has significant limitations. It may reduce certain irritants or bulking agents but fails to remove levamisole, which shares low solubility in acetone with cocaine, allowing it to persist and contribute to severe health effects upon consumption. Levamisole exposure via adulterated cocaine induces syndromes distinct from pure cocaine toxicity, primarily ANCA-associated vasculitis characterized by cutaneous purpura, ear necrosis, and arthralgias, often resolving upon cessation but with risks of permanent tissue damage.[195] [196] Agranulocytosis, marked by severe neutropenia (absolute neutrophil count below 500 cells/μL), occurs in susceptible individuals due to levamisole's immunomodulatory effects, increasing infection susceptibility and reported in multiple case series among chronic users.[197] [198] Renal involvement, including pauci-immune glomerulonephritis, has been documented in biopsy-confirmed cases, with antineutrophil cytoplasmic antibodies (p-ANCA and atypical ANCA) present in over 90% of affected patients.[199] Cocaine is sometimes adulterated with methamphetamine, though this is uncommon and not among the most frequent cutting agents, which typically include levamisole, lidocaine, caffeine, other local anesthetics, and inert diluents such as laxatives (e.g., mannitol), talcum powder, and baking soda.[200] Amphetamines, including methamphetamine, are occasionally added to mimic or enhance cocaine's stimulant effects despite their pharmacological differences. Reports indicate instances where dealers mix crack cocaine with methamphetamine and sell it as regular crack, potentially increasing risks due to combined stimulant effects.[200] Fentanyl adulteration in cocaine, though less prevalent than levamisole (detected in under 4% of samples through 2023), contributes disproportionately to overdose mortality by introducing unintended opioid effects, with cocaine-involved deaths reaching 29,449 in 2023, many co-involving fentanyl.[201] [202] This co-occurrence drives acute respiratory depression and hypoxic fatalities in non-opioid-tolerant users, as evidenced by toxicology data from overdose spikes where fentanyl was present in 84.3% of cases alongside cocaine in 46.1%.[203] Harm reduction testing services report rising fentanyl-cocaine mixtures in urban areas, underscoring adulteration's role in escalating polydrug risks amid black market unpredictability.[204]Oral and Dental Effects
Direct contact with cocaine powder via gumming (rubbing on the gums) or prolonged oral holding causes a pronounced numbing sensation due to cocaine's local anesthetic properties—it blocks voltage-gated sodium channels in nerve endings, preventing sensation transmission. This numbness is often sought for its pleasurable or analgesic effect and is sometimes used as an informal test of purity (stronger numbing suggesting higher quality, though inaccurate due to common adulterants like lidocaine). However, this practice leads to significant damage to oral tissues. Cocaine's acidity (when mixed with saliva) erodes tooth enamel, exposing dentin and increasing decay risk. Vasoconstriction reduces blood supply, leading to tissue ischemia, ulceration, and gum recession. Chronic dry mouth (xerostomia) from reduced saliva promotes bacterial growth and rapid caries. Bruxism (jaw clenching/grinding) accelerates tooth wear and can cause temporomandibular joint issues. Long-term users may experience severe "coke mouth" with infections, bone loss, and permanent dental destruction requiring extensive restoration or extractions. Snorting can also cause secondary oral numbness if powder drips into the mouth.Overdose Mechanisms and Management
Cocaine overdose manifests through sympathomimetic overstimulation, precipitating central nervous system excitation that culminates in seizures, often generalized and refractory to initial anticonvulsants due to underlying sodium channel blockade and elevated catecholamine surge. Unlike heroin, which primarily causes overdose via opioid receptor agonism leading to respiratory depression and failure, cocaine overdose involves cardiovascular collapse, heart attack, stroke, or seizures from excessive stimulation.[205] Hyperthermia, frequently exceeding 40°C and reaching up to 45°C, arises from impaired thermoregulation via hypothalamic disruption and increased metabolic heat production, serving as a prognostic indicator of severity and contributing to multi-organ failure.[205] [206] Rhabdomyolysis emerges secondary to muscle hyperactivity, vasoconstriction-induced ischemia, direct myotoxicity, and exacerbated by hyperpyrexia, leading to elevated creatine kinase levels and potential acute kidney injury.[207] [208] Lethal dose thresholds in humans remain imprecise owing to route of administration, tolerance, and adulterants, with animal models indicating an LD50 of approximately 93 mg/kg intraperitoneally in mice, though human case series report postmortem blood cocaine concentrations in fatalities ranging widely from 0.1 to over 10 mg/L, underscoring variability rather than fixed toxicity benchmarks.[206] [209] No specific antidote exists for cocaine toxicity; management relies on supportive interventions, including high-dose benzodiazepines such as lorazepam or diazepam titrated to control agitation, seizures, and sympathetic hyperactivity, often requiring intubation for airway protection in severe cases.[210] [205] Active cooling protocols—employing ice packs, evaporative methods, and dantrolene if malignant hyperthermia-like states persist—address hyperthermia to mitigate rhabdomyolysis progression, alongside fluid resuscitation and monitoring for arrhythmias or renal complications.[210] [211] Empirical data from emergency department cohorts indicate survival rates exceeding 90% with prompt supportive care in non-cardiac-arrest presentations, though outcomes deteriorate with delayed intervention or comorbidities; polydrug involvement predominates, with 79.1% of cocaine-associated overdose deaths in 2023 co-involving opioids, complicating resuscitation due to synergistic respiratory depression and masking pure cocaine toxicity.[212] Recent 2024-2025 surveillance reflects this trend, as cocaine-related fatalities, while declining 25% in some metrics, frequently entangle with synthetic opioids amid broader stimulant-opioid polysubstance epidemics.[128] [212]Dependence and Withdrawal
Neurobiological Basis of Addiction
Cocaine exerts its reinforcing effects primarily by inhibiting the dopamine transporter (DAT), thereby blocking reuptake of dopamine (DA) released into the synaptic cleft, which results in elevated extracellular DA levels in the nucleus accumbens (NAc), a core component of the mesolimbic reward pathway originating from the ventral tegmental area (VTA).[213] This acute surge in DA signaling activates D1-like receptors on medium spiny neurons in the NAc, promoting gene expression changes that reinforce drug-seeking behavior through enhanced incentive salience.[41] This potent reinforcement contributes to the rapid onset of dependence, with epidemiological evidence indicating quick progression from initial use to cocaine dependence in susceptible individuals.[5] With repeated exposure, neuroadaptations emerge that sustain addiction, including the persistent accumulation of the transcription factor ΔFosB in the NAc and other reward-related regions.[214] ΔFosB, a truncated isoform of FosB, resists proteasomal degradation and builds up over days to weeks, altering chromatin structure and upregulating genes such as Cdk5 and dynorphin that amplify responsiveness to cocaine cues and diminish sensitivity to natural rewards.[215] This molecular switch shifts behavior from hedonic pursuit to compulsive habit formation, as evidenced by viral overexpression studies in rodents where ΔFosB elevation mimics chronic cocaine-induced incentive motivation for the drug.[216] Orexin (hypocretin) neurons and receptors contribute to cocaine addiction neurobiology, particularly in cue-induced seeking and reinstatement. Chronic cocaine administration induces long-lasting up-regulation of orexin receptor type 2 (OX2R) protein levels in the nucleus accumbens.[217] Orexin-1 receptor (OX1R) signaling enhances motivation for cocaine-associated cues, facilitating reinstatement of drug-seeking behavior.[218] Genetic factors contribute substantially to vulnerability, with twin and family studies estimating heritability of cocaine use disorder at 40-60%, supported by genome-wide association studies (GWAS) identifying variants in DA-related genes like DAT1 and DRD2.[219] [220] These polygenic influences interact with environmental exposures to modulate reward sensitivity, though no single locus accounts for more than a small fraction of risk, underscoring addiction's multifactorial etiology.[221] Tolerance develops through homeostatic adaptations, notably downregulation of postsynaptic D2 DA receptors in the striatum, reducing inhibitory feedback and necessitating higher doses for equivalent euphoria.[222] Chronic cocaine exposure also attenuates presynaptic DA release dynamics in the NAc core, further dysregulating the reward circuitry.[223] Tolerance to cocaine's euphoric, cardiovascular, and subjective effects develops with repeated use, with no universal threshold dose or concentration marking its onset. Acute tolerance can occur within a single binge session, reducing effects despite sustained blood levels. Chronic tolerance involves adaptations in dopamine systems, requiring higher doses for similar effects. This drives escalation of use, increasing risks of overdose and toxicity, as tolerance provides limited protection against lethal effects. Animal self-administration models demonstrate addiction's volitional core via reinstatement paradigms, where extinguished cocaine seeking is robustly revived by cues, stress, or low-dose priming, implicating VTA-NAc projections and prefrontal inputs in persistent craving independent of acute withdrawal.[224] Unlike mere physiological dependence, which involves adaptive changes reversible upon abstinence, addiction manifests as maladaptive plasticity driving relapse despite adverse consequences, as quantified by escalated lever-pressing in rodents under progressive ratio schedules.[225] This distinction highlights compulsion as a hallmark, rooted in sensitized subcortical circuits overriding executive control.[226]Withdrawal Symptoms and Treatment
Cocaine withdrawal manifests in two primary phases following cessation of use. The initial "crash" phase, occurring within hours to days after the last dose, is characterized by profound fatigue, hypersomnia lasting up to several days, severe anhedonia, increased appetite, and psychomotor retardation.[227][228] Intense drug cravings, irritability, and dysphoric mood also emerge during this period, driven by the abrupt depletion of dopamine following chronic stimulation.[227] The protracted withdrawal phase extends for weeks to months, featuring persistent anxiety, depression, and anhedonia that can mimic major depressive disorder, alongside ongoing cravings that heighten relapse vulnerability.[228] These symptoms lack the life-threatening autonomic hyperactivity seen in alcohol or opioid withdrawal but, unlike heroin withdrawal which involves severe physical symptoms such as nausea, vomiting, diarrhea, muscle aches, piloerection, and flu-like illness, cocaine withdrawal is predominantly psychological with depression, fatigue, and increased appetite, though both substances carry high risks of addiction and relapse. Severity correlates to pretreatment use intensity and duration.[227][229] No medications are FDA-approved specifically for cocaine withdrawal, though symptomatic management may include antidepressants or anxiolytics for severe mood disturbances, with limited empirical support for dopamine agonists like modafinil in reducing cravings.[230] Behavioral interventions predominate, with contingency management (CM)—providing tangible reinforcers for verified abstinence via urine tests—demonstrating superior short-term efficacy in promoting abstinence compared to cognitive-behavioral therapy (CBT) alone, yielding up to three times longer periods of sustained abstinence in randomized trials.[231][230] Residential treatment programs show higher initial abstinence rates than outpatient settings, particularly for severe dependence, but both formats face high relapse, with meta-analyses indicating 60-90% of individuals resuming use within one year post-treatment due to cue-induced cravings and environmental triggers.[232][233] CM's effects often wane after reinforcement cessation, underscoring the need for extended or adaptive protocols, though implementation barriers like cost limit widespread adoption.[234] CBT focuses on coping skills and relapse prevention but yields more modest abstinence gains without CM augmentation.[230]Drug Interactions
Interactions with Common Substances
Cocaine combined with alcohol produces cocaethylene via liver transesterification, a metabolite with a longer half-life than cocaine (approximately 2-3 hours versus 0.5-1.5 hours for cocaine), thereby prolonging central nervous system stimulation and euphoria while heightening risks of sudden death, with cocaethylene exhibiting greater cardiotoxicity and hepatotoxicity than the parent compounds.[235][236] Cocaethylene increases sexual desire and arousal but impairs performance by making it harder to achieve erection, lubrication, and orgasm, often leading to prolonged attempts at sexual activity, with potential for increased intensity of desire but reduced physical satisfaction, frustration, physical damage, and higher STI risk due to disinhibited behaviors; sexual dysfunction is common, affecting 62% of male dual abusers.[237][238] This interaction elevates liver enzyme levels and fibrosis markers in chronic users, independent of viral hepatitis status.[239] Co-use with opioids, as in "speedball" mixtures of cocaine and heroin, synergistically increases overdose lethality; cocaine's sympathomimetic arousal obscures early opioid-induced respiratory depression, prompting higher opioid intake and subsequent profound hypoxia when cocaine effects wane, contributing to cocaine's presence in about 20% of opioid overdose fatalities.[240][241] Concurrent administration with monoamine oxidase inhibitors (MAOIs) risks hypertensive crisis, as cocaine's inhibition of norepinephrine reuptake combines with MAOI blockade of monoamine catabolism, causing unchecked sympathetic surge and potential vascular rupture or myocardial infarction.[242][243] Cannabis modulates cocaine's reinforcement; adolescent THC exposure potentiates cocaine self-administration in rodents under low-dose conditions, likely via enhanced dopamine signaling in the nucleus accumbens, though acute co-administration may blunt peak cocaine plasma levels and subjective highs in humans.[244][245] Nicotine augments cocaine reinforcement, shifting progressive-ratio breakpoints upward in self-administration paradigms and priming striatal histone modifications that heighten cocaine-induced locomotor sensitization and reward salience.[246][247]Pharmacological Contraindications
Cocaine hydrochloride is contraindicated in patients with known hypersensitivity to the drug or its components, as well as in those with epilepsy, due to risks of seizures and other neurological complications.[248][3] In individuals with preexisting cardiovascular disease, cocaine administration is contraindicated owing to its potent sympathomimetic effects, which elevate heart rate, blood pressure, and myocardial oxygen demand, precipitating acute events such as myocardial infarction (odds ratio 3.8–6.9 compared to nonusers) and arrhythmias.[132] Clinical trials for cocaine-based anesthetics routinely exclude patients with coronary artery disease, hypertension, or cardiomyopathy to mitigate these amplified risks.[150] Cocaine is contraindicated in patients with glaucoma, as it induces mydriasis and elevates intraocular pressure, potentially triggering acute angle-closure glaucoma in susceptible individuals; cohort studies report a 45% increased glaucoma risk (adjusted odds ratio approximately 1.45) among users.[249][250] During pregnancy, cocaine exposure is contraindicated due to teratogenic effects documented in epidemiological data, including congenital cardiac malformations, genitourinary defects, and gastrointestinal anomalies, alongside obstetric complications such as placental abruption (relative risk up to 4-fold) and preterm delivery.[251][252] Prenatal exposure also correlates with intrauterine growth restriction and low birth weight, with animal models confirming disrupted fetal neurodevelopment.[253] Breastfeeding mothers must avoid cocaine, as the drug achieves high concentrations in breast milk—exceeding maternal plasma levels—potentially causing infant toxicity, including irritability, tremors, and cardiovascular instability; lactation databases recommend complete abstinence.[254] Patients with a history of psychiatric disorders face contraindication due to cocaine's propensity to induce or exacerbate psychosis, paranoia, and mood disturbances; clinical observations link prior exposure to heightened suspiciousness and delusional states, with chronic users showing amplified symptom severity in comorbid conditions like schizophrenia or bipolar disorder.[116] Trial protocols for cocaine exclude such histories to prevent acute decompensation, where odds of psychotic episodes rise substantially in vulnerable populations.[255]Legal Status and Policy
International Frameworks
The Single Convention on Narcotic Drugs, adopted by the United Nations on March 25, 1961, classifies cocaine as a Schedule I substance, subjecting it to the strictest controls due to its high potential for abuse and lack of accepted medical value internationally, thereby prohibiting non-medical production, manufacture, and trade.[256] This convention, ratified by 186 parties as of 2024, aims to limit narcotic drugs to medical and scientific purposes while eradicating illicit cultivation of opium poppy, coca bush, and cannabis plant.[257] The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, signed on December 19, 1988, builds on the 1961 framework by establishing controls over chemical precursors used in cocaine production, such as potassium permanganate for oxidation and sulfuric acid for extraction, listed in Tables I and II for mandatory monitoring, licensing, and reporting of international trade.[258] Article 12 requires parties to prevent diversion of these substances into illicit channels, with the International Narcotics Control Board (INCB) overseeing compliance through voluntary assessments and mandatory notifications for exports.[259] Despite these mechanisms, enforcement gaps persist, as evidenced by surging global cocaine production; the United Nations Office on Drugs and Crime (UNODC) reported a record 3,708 tons in 2023, a 34% increase from 2022 and over four times the output a decade prior, driven primarily by expanded coca cultivation in Colombia, Ecuador, and Peru.[124][260] The INCB's monitoring, while identifying trafficking surges and purity increases, has proven insufficient to curb supply expansion, with reports noting inadequate precursor controls and weak inter-agency cooperation amid rising illicit outputs.[261] Sovereignty tensions underscore implementation challenges, particularly regarding coca leaf allowances; Bolivia rejoined the 1961 Convention in 2013 with a reservation permitting traditional uses like chewing and tea consumption for up to 22,000 hectares of legal cultivation, defying the treaty's broader prohibition on non-pharmaceutical coca processing.[262] This exception, opposed by some parties like the United States, highlights conflicts between universal treaty obligations and national assertions of cultural rights, with Bolivia's ongoing campaigns to deschedule coca leaf entirely—renewed in 2025—further straining consensus on the conventions' scope.[263]National Regulations and Variations
In the United States, cocaine is classified as a Schedule II controlled substance under the Controlled Substances Act, permitting limited medical applications such as local anesthesia while prohibiting non-medical possession, distribution, or manufacture, with penalties including up to 20 years imprisonment for trafficking.[264][265] Both powder and crack forms are Schedule II, though federal sentencing guidelines historically imposed harsher penalties for crack—reduced from a 100:1 to an 18:1 quantity ratio via the 2010 Fair Sentencing Act—with ongoing disparities contributing to racial sentencing inequities; as of 2025, bills like the EQUAL Act seek full parity but remain unpassed.[266][267] Oregon's 2020 Measure 110 decriminalized possession of small amounts (under 1 gram) by replacing criminal penalties with civil fines and treatment referrals, but amid rising overdoses (from 280 in 2019 to 1,300 by 2023) and public disorder, lawmakers recriminalized it as a misdemeanor effective September 1, 2024, via House Bill 4035.[268][269]| Country | Classification | Key Provisions |
|---|---|---|
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession punishable by up to 7 years imprisonment; supply or production up to life; no medical use beyond trace amounts in preparations.[270][271] |
| Australia | Schedule 8/9 prohibited drug (federal/state laws) | Possession illegal with penalties varying by state (e.g., up to 25 years for trafficking); Australian Capital Territory's 2023 laws impose fines for small amounts but retain criminal sanctions for cocaine supply.[272][273] |